

MEETING
STATE OF CALIFORNIA
AIR RESOURCES BOARD
SCIENTIFIC REVIEW PANEL

CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY
SIERRA HEARING ROOM
1001 I STREET
SACRAMENTO, CALIFORNIA

THURSDAY, APRIL 5, 2012
10:29 A.M.

TIFFANY C. KRAFT, CSR
CERTIFIED SHORTHAND REPORTER
LICENSE NUMBER 12277

APPEARANCES

PANEL MEMBERS

Stanton A. Glantz, Ph.D., Acting Chairperson

John R. Froines, Ph.D., (via teleconference)

Alan R. Buckpitt, Ph.D.

Sarjeet Gill, Ph.D.

William W. Nazaroff, Ph.D.

REPRESENTING THE AIR RESOURCES BOARD:

Mr. Jim Behrmann, Liaison, Scientific Review Panel

Mr. Peter Mathews, SRP Support Administration

REPRESENTING THE OFFICE OF ENVIRONMENTAL HEALTH HAZARD
ASSESSMENT:

Dr. George Alexeeff, Director

Dr. Robert Blaisdell, Supervisor, Environmental Modeling
Section

Dr. Daryn Dodge, Staff Toxicologist

Dr. Melanie Marty, Chief, Air Toxicology and Epidemiology
Branch

ALSO PRESENT

Mr. Brian R. Leahy, Director, Department of Pesticide
Regulation

INDEX

	<u>PAGE</u>
1. Review of the draft report "Air Toxics Hot Spots Program Technical Support Document for Exposure Assessment and Stochastic Analysis" (February 2012)	6
2. Consideration of a request that the Scientific Review Panel receive oral testimony at its meetings.	133
3. Consideration of administrative matters.	134
4. Adjournment	134
5. Reporter's Certificate	135

1 when I think of this Committee. So I'm glad that we're
2 making progress, and it's a real pleasure to be here.

3 ACTING CHAIRPERSON GLANTZ: Well, thank you for
4 coming. I hope we entertain you adequately.

5 DEPARTMENT OF PESTICIDE REGULATIONS DIRECTOR
6 LEAHY: I hope so, too.

7 ACTING CHAIRPERSON GLANTZ: So I think I'll
8 begin -- the other bit of news I heard is George Alexeeff
9 is now the Director of the Office of Environmental Health
10 Hazards. After being Acting Director for some protracted
11 period of time, do you want to say anything, George?
12 Congratulations, I think.

13 OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
14 DIRECTOR ALEXEEFF: I'm George Alexeeff. I was appointed
15 Director a couple weeks ago. I was Acting Director for a
16 little over a year.

17 So I want to make a couple comments. One is
18 because when I was first hired by the State, my task was
19 to develop a document for review by this Committee. And
20 it was on carbon tetrachloride. After that, I developed
21 perchlorethylene, methylene chloride. And my life was
22 very closely tied to this Panel when I first started. And
23 then I moved up through the ranks into this position. So
24 I've always been very fond of this Committee and the work
25 of this Committee and the importance of this Committee.

1 And I just wanted to make one brief comment is
2 that, you know, in looking at the kind of information we
3 provide to you today is a little bit different kind of a
4 document than we normally have. We're usually looking at
5 some sort of human health or some sort of health
6 information and trying to figure out whether we can
7 develop a reference level or a cancer slope factor or
8 something like that.

9 But when we're looking at the data, we're seeing
10 that we're kind of -- we're starting to run out of the
11 type of data that we normally look at and provide to the
12 Committee in terms of animal testing data or human data.
13 So we're going to have to figure out a way of working with
14 the Committee and looking at invetro data coming in and
15 looking at incorporating that in a way that would be
16 health protective and such.

17 So I'm looking forward to working on the
18 Committee with that and seeing what we can do. That's
19 something U.S. EPA is also trying to figure out as well.
20 It's a known fact that we have in some ways too many
21 chemicals and not enough data or enough animals or enough
22 data, whatever we want to call it, so we have to look at
23 new ways of trying to figure out how to identify chemicals
24 of concern so they can be addressed. So thank you very
25 much.

1 PANEL MEMBER FROINES: George, can you hear me?

2 ACTING CHAIRPERSON GLANTZ: Yes, John. Hello.

3 PANEL MEMBER FROINES: Hi. Congratulations.

4 I just wanted to say I would like to propose,
5 based on what you just said, that we have a meeting -- one
6 of the topics at a meeting at some point in the future is
7 the whole idea of new toxicity testing and predictive
8 toxicology. Because I think those kinds of end points,
9 cellular end points -- invetro end points are going to
10 become more and more important over time with ToxCast and
11 Tox21. And I think the Panel would benefit from being
12 familiar with the EPA and NIEHS activities in those areas.
13 And we don't need to take a long time. But I think a
14 short presentation and discussion would be useful.

15 OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
16 DIRECTOR ALEXEEFF: That sounds great. Thank you.

17 ACTING CHAIRPERSON GLANTZ: Any of the members
18 want to say anything?

19 Okay. Well, I've been on this Committee the
20 second longest time behind John Froines. And I remember
21 you coming in. We were all, like, younger. I think
22 Melanie was pregnant. How old is your kid now?

23 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
24 MARTY: The youngest is almost 23.

25 ACTING CHAIRPERSON GLANTZ: So, yeah. I don't

1 know if it's good or depressing. Well, anyway, so why
2 don't we just -- I guess I would just say one introductory
3 comment about this report. And this is an update of an
4 earlier report that was from 2000 -- right -- 2000, which
5 I was the lead person on and volunteered to be the lead
6 person on this one. I didn't realize it would be like
7 three times this thick.

8 But the basic idea of this report or the
9 procedures developed in the first report, which I think
10 were quite innovative for the time, were rather than just
11 taking point estimates sort of average values or 95
12 percentile values or exposure for various biological
13 process parameters and just multiplying all of those
14 together to actually try to take into account the
15 distributional characteristics of the exposures and of the
16 various biological variables. And I think that may well
17 have been the first time anybody tried to do that.

18 And what this report represents -- I'm also the
19 lead on this one -- is a further refinement of the basic
20 approaches that were used then. And I think there are two
21 things that have changed since the first report. One is
22 the amount of data available upon which to base such
23 modeling efforts, although it's still not perfect.

24 And also I think the computational capabilities
25 and the software that's available to support this kind of

1 modeling is much, much, much better than it was in 2000.

2 So with that little bit of introduction, I'll
3 turn it over to Melanie and hopefully the slides are now
4 numbered. Was that the big controversy?

5 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF MARTY:
6 That was the big PowerPoint 210 stumped us in terms of
7 being able to number the slides. Pretty hard for John to
8 follow.

9 ACTING CHAIRPERSON GLANTZ: Back converting to
10 PowerPoint 2007. Was that the solution?

11 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF MARTY:
12 You have to ask Dr. Andy Salmon Wizard how he did it.

13 PANEL MEMBER FROINES: Can I make one
14 announcement that Stan wasn't aware of, I think?

15 We have a new member of the SRP. And her name is
16 Beate Ritz, and she's an epidemiologist and she's at
17 U.C.L.A. So we have a new person to join the Committee.

18 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF MARTY:
19 Okay. I'm going to start by -- well, first I should
20 introduce myself for the court reporter.

21 I'm Melanie Marty, the Chief of the Air
22 Toxicology and Epidemiology Branch at OEHHA. And today
23 we're going to hear a presentation about the Revised Hot
24 Spots Exposure Assessment and Stochastic Analysis
25 Guidelines.

1 Dr. Bob Blaisdell, the Section Manager of our
2 Exposure Monitoring, and Daryn Dodge, our toxicologist,
3 are going to give the presentation.

4 So Bob, take it away.

5 (Thereupon an overhead presentation was
6 presented as follows.)

7 DR. BLAISDELL: So Daryn and I are going to be
8 switching back and forth as we go through this
9 presentation. It's a somewhat lengthy presentation, as
10 the document is. So if you have questions, please
11 interrupt.

12 ACTING CHAIRPERSON GLANTZ: Let me just -- do you
13 think because the document -- and I'd like to get a sense
14 of the Committee.

15 Since the document is so long, do you want to
16 have them do the whole -- how many slides is the whole
17 presentation? Fifty-four.

18 Do you want to hear the whole presentation before
19 we start talking about it? Or do you want to have them
20 kind of go through it in pieces and then stop and discuss
21 it or just interrupt with questions or what do people want
22 to do? Because it is a very long document.

23 PANEL MEMBER NAZAROFF: I don't know how to
24 answer your question, Stan, but let me give you input you
25 might use to judge.

1 I have a total of 47 comments that vary from sort
2 of the T crossing, I dotting that don't need to be
3 presented here. I've just e-mailed them to Melanie like
4 15 minutes ago. But some of them are really substantive.

5 And I guess my preference -- I will answer your
6 question -- is to hear what the OEHHA folks have to tell
7 us and then get into the whole substance because the
8 comments go across the whole document. It seems like it's
9 going to be hard to organize by section.

10 ACTING CHAIRPERSON GLANTZ: Okay.

11 PANEL MEMBER BUCKPITT: That makes sense.

12 PANEL MEMBER GILL: I think that's better.

13 ACTING CHAIRPERSON GLANTZ: Okay. Go on.

14 DR. BLAISDELL: First of all, these are the main
15 people who worked on --

16 PANEL MEMBER FROINES: Can I interrupt? I wasn't
17 quite clear on Bill's comment. Are we to interrupt during
18 the presentation or not?

19 ACTING CHAIRPERSON GLANTZ: No. We decided to
20 just let them go through the whole presentation. I think
21 if there's some burning point we could, but let's try to
22 get them get through the whole thing.

23 PANEL MEMBER FROINES: That's okay.

24 DR. BLAISDELL: Okay. This is a list of the many
25 people who were authors and reviewers and project leads on

1 this document.

2 --o0o--

3 DR. BLAISDELL: I'd like to give some background
4 on the Air Toxics Hot Spots Program.

5 The stationary sources in California report
6 emissions of a specified list of chemicals to the Air
7 Resources Board and the local Air Pollution Control
8 Districts.

9 Facilities are prioritized by the districts into
10 three categories: High, medium, and low concern. And
11 this is based on emission estimates, distance to nearest
12 receptor, information on potency of toxicants, and
13 worst-case meteorology.

14 Facilities that sort of flunk the initial
15 screening are required to conduct a health risk assessment
16 to estimate public health impacts to the surrounding
17 population from facility emissions. The Air Toxics Hot
18 Spots Program is a Public Right to Know Act. So the
19 facilities are required to hold a public meeting and
20 notify the residents.

21 --o0o--

22 DR. BLAISDELL: One of the advantages of this
23 program is that the risk management activities by the
24 local air districts can be prioritized based on the
25 results of the risk assessments. The Air Resources Board

1 uses the results of risk assessments to determine the need
2 for and to design air toxics control measures that apply
3 to classes of industries and types of industrial
4 activities, such as chrome plating.

5 --o0o--

6 DR. BLAISDELL: OEHHA's role, as specified in the
7 statute, the statute requires risk assessments to be
8 conducted in accordance with guidelines developed by
9 OEHHA.

10 OEHHA created technical support documents to lay
11 out the underlying science and methods that were first
12 adopted in -- these guidelines were first adopted in 1999
13 to 2000.

14 OEHHA revised technical support documents after
15 passage of SB 25, which required more explicit
16 consideration of infants and children, both in terms of
17 exposure and potential sensitivities relative to adults.

18 The non-cancer and cancer dose response
19 assessment guidance was approved following SRP review in
20 2008 and 2009.

21 OEHHA is also required to review all risk
22 assessments produced by the facilities. These are sent to
23 us by the districts, and our findings are conveyed to the
24 district in a letter.

25 The exposure guidelines, which is the final part,

1 are undergoing your review now.

2 --o0o--

3 DR. BLAISDELL: The Hot Spots Exposure Guidelines
4 need to be practical and yet apply to many different
5 situations throughout the state, adaptable to different
6 scenarios and types of facilities. And they need to be
7 useful to do comparisons of potential health impacts and
8 risks across facilities so the methods need to be
9 standardized. And above all, they need to be protective
10 of public health.

11 --o0o--

12 DR. BLAISDELL: Why did we undertake this
13 revision? As I mentioned before, in part, it was to
14 consider -- to reconsider infants and children under our
15 SB 25 mandate. The revision of the exposure assessment
16 guidance was prompted by the recognition of greater risk
17 for early in life exposure.

18 The revisions incorporate the latest scientific
19 data on exposure and fate and transport. A large body of
20 literature became available since our last version in
21 2000. This presentation focuses on the major changes to
22 the document.

23 --o0o--

24 DR. BLAISDELL: We needed exposure variants for
25 different age ranges than in the previous guidance.

1 The cancer risk for exposures from the third
2 trimester to less than two years is weighted 10X.

3 Cancer risk for exposures from two to less than
4 16 years is weighted 3X.

5 Exposure is greater earlier in life because of
6 behavioral, physiological differences, biochemical
7 differences, and therefore risk needs to be separately
8 calculated for each age range and then summed. Therefore,
9 we needed exposure variants for different age ranges
10 corresponding to these specific age groups.

11 --o0o--

12 DR. BLAISDELL: Also, cancer risk needed to be
13 calculated for different residential exposure durations of
14 9, 30, and 70 years, which meant that we needed still more
15 age ranges.

16 This is an example of calculation of cancer risk
17 from the third trimester to age 30. And essentially, you
18 calculate the average daily dose for the third trimester
19 times the cancer potency factor, times ten, which is the
20 age sensitivity factor, times the proportion of 70 years
21 that the third trimester represents, which is .3. And
22 then add it to the average daily dose from age zero to 2,
23 times the cancer potency factor, times ten, which is the
24 age sensitivity factor times 2/70th, so on, so forth.

25 So, therefore, we need exposure variants from 0

1 to 2, 2 to 9, 9 to 16, 16 to 30. And that actually should
2 be 16 to 70 on the last one.

3 --o0o--

4 DR. BLAISDELL: These are the pathways that are
5 evaluated under the Hot Spots Program. All chemicals are
6 evaluated for inhalation. There are also chemicals that
7 are subject to deposition in the Hot Spots Program. And
8 those are evaluated by the dermal and soil injection
9 pathways at least.

10 Some chemicals can be transferred to mother's
11 milk. So we evaluate that pathway, too.

12 We have a provision for home grown produce, home
13 raised meats, chicken, beef, and pork, home raised eggs,
14 angler caught fish, if there is a pond where people fish.
15 And we also put the facility. Drinking water from local
16 surface waters. We don't worry about reservoirs, and so
17 on.

18 These pathways, the pathways that are in an
19 individual risk assessment, depend on the chemical and the
20 physical chemical properties. And also at the particular
21 site there needs to be a completed pathway. In other
22 words, if the facility is out in the desert in California,
23 there may not be any vegetable gardens around. So that
24 pathway is not considered, even though we have a chemical,
25 which is subject to deposition.

1 --o0o--

2 DR. BLAISDELL: So only non-volatile and
3 semi-volatile chemicals are evaluated in the Hot Spots
4 Program for the non-inhalation pathways, because the
5 chemical is originally airborne. And there is not any
6 significant exposure to volatile organics by other
7 pathways.

8 The non- and semi-volatiles include some
9 important toxicants, however such as polycyclic aromatic
10 hydrocarbons, dioxins, furans, mercury, lead, and
11 hexavalent chromium. Thus, we have exposure variants for
12 all significant pathways of exposure that can occur with
13 airborne deposition.

14 --o0o--

15 DR. BLAISDELL: Facilities, according to the
16 legislation, have the option of presenting alternative
17 site risk assessments. OEHHA provided guidance for this
18 in 2000 and essentially this hasn't changed. Essentially,
19 the facility can present anything that they want in this
20 risk assessment, but we provided some guidance in terms of
21 what we would be looking for if we reviewed an alternative
22 risk assessment.

23 The first Tier 1 is a point estimate approach and
24 uses the OEHHA recommended point estimates, which you see
25 in the document.

1 Tier 2 would be a point estimate approach that
2 uses justified site-specific point estimates. In other
3 words, somebody has a pond and people are fishing in that
4 pond. And they don't like our estimate of fish
5 consumption and they can figure out a way to more
6 accurately estimate fish consumption, they might
7 incorporate that into a Tier 2 risk assessment.

8 A Tier 3 would be a stochastic approach using the
9 OEHHA recommended distributions.

10 And a Tier 4 approach would be a stochastic
11 approach with site-specific distributions that the
12 facility would come up with.

13 We have gotten a few alternative risk assessments
14 over the years. I don't think that we've really gotten
15 any Tier 2 -- or actually, the only thing I think we've
16 seen really is the Tier 1 risk assessments, which all
17 facilities are required to do.

18 ACTING CHAIRPERSON GLANTZ: I just have one
19 clarifying question. When you say justified, who makes
20 the decision if they're justified?

21 DR. BLAISDELL: Well, essentially what we'd be
22 looking for is some sort of database.

23 ACTING CHAIRPERSON GLANTZ: But it's OEHHA who
24 has to accept the justification?

25 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

1 MARTY: OEHHA has to review the document and accept the
2 justification for the alternative.

3 DR. BLAISDELL: If we comment, if we didn't feel
4 that it was justified. We're just trying to let the
5 facilities know that you just can't make something up and
6 have it viewed favorably by our office.

7 ACTING CHAIRPERSON GLANTZ: Okay.

8 DR. BLAISDELL: Okay. Most of the OEHHA
9 distributions and point estimates in this document have
10 been revised relative to the 2000 document because there
11 was a lot of newer data available.

12 One of the things that we managed to do is come
13 up with a stochastic approach for the dermal pathway,
14 whereas in the previous document there was only a point
15 estimate approach.

16 --o0o--

17 DR. BLAISDELL: There is a piece of legislation
18 that was passed a few years back called SB 352. SB 352
19 required a risk assessment for proposed school sites that
20 were to be located within 100 yards of a busy roadway. It
21 didn't necessarily ban the school site from consideration
22 by the local district, but it said a risk assessment had
23 to be done. And it specified the use of the hot spots
24 risk assessment procedures, but the 2000 document only had
25 24-hour breathing rates and eight-hour worker breathing

1 rates.

2 So we included some information in this revised
3 exposure assessment stochastic analysis document such as
4 one-hour breathing rates at various activities that could
5 be estimated to use a breathing rate during a school day
6 with different activities because activity levels at a
7 school site will vary quite a bit. In other words, it can
8 be in the classroom or out on the track. So we wanted to
9 provide some tools for SB 352.

10 PANEL MEMBER FROINES: Can I answer a question?

11 DR. BLAISDELL: Sure.

12 PANEL MEMBER FROINES: Just to clarify. In
13 schools, teachers work many times longer than eight hours.
14 And eight hours is the traditional view, but it's not
15 really adequate. And it seems to me that needs to be
16 discussed further.

17 DR. BLAISDELL: Okay. We can certainly include
18 something --

19 ACTING CHAIRPERSON GLANTZ: Why don't we come
20 back to the specific issues after they've got through the
21 whole report though. Why don't we make a note of that and
22 we'll come back to that. Go on.

23 UNIDENTIFIED AUDIENCE SPEAKER: I have a quick
24 point. What's the difference between point estimate and
25 stochastic estimate briefly?

1 ACTING CHAIRPERSON GLANTZ: Why don't -- let's
2 see when's the best place -- a person in the audience just
3 asked what's the difference between a point and stochastic
4 estimate. That's a good point worth making.

5 Rather than interrupting the presentation, at
6 some logical place as you start getting into talking about
7 the actual modeling, why don't you address that. Okay.
8 That's a reasonable thing to talk about. But I think
9 there is probably a place you can just sort of address
10 that as you're going along.

11 DR. BLAISDELL: Okay. I'm going to go through
12 the --

13 --o0o--

14 DR. BLAISDELL: Daryn and I are going to go
15 through the various chapters here.

16 ACTING CHAIRPERSON GLANTZ: Actually, having said
17 that, this might be a place to answer that question. So
18 do you want to say something? Or, Melanie, did you
19 just -- I mean, I think you can answer very quickly.

20 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
21 MARTY: The point estimate approach is where you estimate
22 cancer risk, assuming a single -- that everyone breathes
23 at the same rate, for example. A stochastic approach
24 incorporates variabilities in the exposure so you end up
25 with a range of cancer risks primarily based on

1 variability in the exposure.

2 ACTING CHAIRPERSON GLANTZ: Just to expand
3 slightly on that, I mean, basically, the process that's
4 described in this document as you come up with a way of
5 estimating exposure to some chemical, then absorption of
6 the chemical, the biological effects of the chemical, and
7 the different end points that were listed. And a point
8 estimate is to take the best estimate of each of those
9 numbers -- and they'll be talking at some length about how
10 they define the best number and just basically putting all
11 of those into the relevant formulas. So you come up with
12 one number.

13 All of these different variables have variation
14 in them because different people are different. The level
15 of exposure will vary because of variation in winds and
16 things like that.

17 So the stochastic model takes into account that
18 variability and then kind of multiplies all those things
19 together. So in the end, instead of getting a single
20 estimate of risk, you get a range of risks and a
21 distribution of risks. Okay.

22 PANEL MEMBER FROINES: I think this is a very
23 important point that -- and National Academy of Science
24 just spoke to this issue in their 2009 report in terms of
25 dealing with uncertainty and variability. So it's

1 important to recognize when you deal with variability
2 you're going to come up with more than one number.

3 ACTING CHAIRPERSON GLANTZ: Yeah, I mean,
4 basically what you do in a stochastic model -- and that
5 stochastic is just a fancy word for take into account the
6 variability. There's really two sources of variability in
7 the numbers that you get. One is just the fact that
8 different people are different, that wind varies, things
9 like that. And then there is also the uncertainty and the
10 estimates, which is something because your estimates
11 aren't perfect. Those end up getting manifest in the same
12 number, the variabilities and the distributions.

13 But one of the issues that needs to be addressed
14 in looking at each of these different end points is if
15 you're going to pick a best number, what should that best
16 number be? And if you're going to account for the
17 variability, what's the shape of the distribution of the
18 parameters and distribution. So that's where we're now
19 going to go through. So does everybody get that?

20 Go ahead.

21 DR. BLAISDELL: So Chapter 2 is the air
22 dispersion modeling chapter. And the Air Resource Board
23 is really the author of this chapter.

24 There are some changes in air modeling procedures
25 presented in this chapter. AERMOD, which is an update

1 from ISCST 3, has been endorsed by the U.S. EPA and that's
2 now recommended for hot spots risk assessments.

3 There is an option for spatial averaging for
4 residential and worker MEI. And the idea behind this is
5 that we base --

6 ACTING CHAIRPERSON GLANTZ: What is MEI in
7 English?

8 DR. BLAISDELL: Maximally exposed individual.

9 PANEL MEMBER FROINES: Stan, may I ask a
10 question? And I'm sorry for interrupting.

11 ACTING CHAIRPERSON GLANTZ: Sure.

12 PANEL MEMBER FROINES: The document said AERMOD
13 has been endorsed by U.S. EPA has now been recommended for
14 hot spot risk assessments. As we saw with, for example,
15 methyl iodide, we didn't agree at all with EPA. So the
16 fact that EPA says something is good doesn't necessarily
17 mean the State of California should say it's good. So
18 that I'm assuming that when you say it's now recommended,
19 you're saying that OEHHA has made a determination that
20 this is an adequate modeling method.

21 ACTING CHAIRPERSON GLANTZ: Okay. But let's let
22 them finish the presentation and then we can come back. I
23 would view that as a more substantive discussion.

24 So what I'm planning to do after the presentation
25 is to basically go through the report one chapter at a

1 time, and you can bring that up when we talk about the air
2 modeling. So I would like -- people wanted to let them
3 get through the presentation, so let's do that.

4 PANEL MEMBER FROINES: You just have the problem
5 of the Chair in Colorado, so I apologize. I recognize the
6 importance of what you're saying.

7 ACTING CHAIRPERSON GLANTZ: I'm pretending to be
8 you, John.

9 PANEL MEMBER FROINES: I apologize. I apologize,
10 because I knew we made an agreement after Bill mentioned
11 what he said.

12 ACTING CHAIRPERSON GLANTZ: Okay.

13 DR. BLAISDELL: There is also an option for
14 spatial averaging.

15 The idea of trying to do spatial averaging came
16 about because for some types of facilities, facilities
17 that are fairly close to the receptor with relatively
18 short stack. And when you determine the highest
19 concentration at the point of maximum impact, the
20 concentration around that point can fall off very rapidly,
21 say within a few feet.

22 So in order to really improve the accuracy of the
23 exposure estimate, the Air Resources Board and OEHHA
24 looked into procedures for averaging the concentration
25 over a larger area to give a more realistic picture of

1 we have now. This is for long-term daily residential
2 continuous exposure for all our various age groups.

3 New to this document is eight-hour breathing
4 rates for cancer risk. These are for exposures only
5 during facility operation of about eight hours per day.
6 It applies to residential neighborhoods, as well as off
7 site workers and schools.

8 And also new is one-hour breathing rates. This
9 was to address the SB 352 mandate for school sites near
10 major roads.

11 --o0o--

12 DR. DODGE: For long-term or chronic exposure
13 breathing rates, we evaluated three approaches for
14 estimating long-term breathing rates. Now, these
15 approaches are all established measures for estimating
16 long-term breathing rates. And by definition, they're all
17 indirect measures in order to get long-term breathing rate
18 averages or distributions.

19 The first approach is called the energy intake or
20 food intake approach. And this looks at food or calories
21 consumed and the fact that it's related to oxygen breathed
22 in and converted to calories to energy. This employs the
23 laten's equation which converts energy to a breathing
24 rate.

25 The second approach is called a metabiologic

1 equivalent approach. And this is essentially a time
2 activity approach similar to what we had relied on in our
3 first or our previous document. This reflects the
4 proportional increase in basal metabolic rate during
5 specific activities. Basal metabolic rate being given a
6 one or slightly less for sleep, for instance.

7 And number three is a doubly labeled water
8 method, which measures CO2 output from the body and the
9 urine. It's also indirect measure of metabolic rate. And
10 this process involves a participant drinking water that is
11 labeled both -- well, one of -- some of the water is
12 labeled on the hydrogen deuterated water and oxygen 18 on
13 others.

14 So the output of these two types of water is then
15 measured in the urine over a one- to three-week period.

16 --o0o--

17 DR. DODGE: Now, the paper we used to estimate
18 breathing rates by the food intake approach is by
19 Arcus-Arth & Blaisdell, 2007. This is based on a large
20 two-day food intake survey of children and adults, known
21 as the "Continuing Survey of Food Intake of Individuals."
22 I'll refer to it as CSFII. This is by USDA in 2000.

23 The advantage of this method is it's a large
24 study. Individual data on food intake, age, body weight,
25 et cetera, and it has nationally representative data for

1 So what we took -- what we did is we took the
2 individual data points and developed distributions based
3 on the data from Brochu, et al.

4 --o0o--

5 DR. DODGE: The advantages of the doubly labeled
6 water approach is that it's the most accurate method for
7 long-term breathing rate estimates. And we had access to
8 a large database.

9 The disadvantage is that the database was not
10 representative of population, but more representative of
11 sub-populations. For example, we had a large group of
12 adults with -- considered normal BMI, or body mass index.
13 And it was separate from a large study that looked at
14 individuals with a high body mass, or BMI index, of 25 or
15 greater.

16 Another disadvantage is that different ages were
17 not sampled equally. There was one study that looked at a
18 lot of five- and six-year-olds, for instance, using this
19 approach and very few that looked at three-year-olds.

20 --o0o--

21 DR. DODGE: So with these three different
22 approaches, these are the mean breathing rates in liters
23 per kilogram day. Now when you normalize the body weight,
24 you're going to find that the infants and children values
25 of breathing rates are going to be higher. As you move to

1 the right to adults, the numbers are going to be smaller.

2 ACTING CHAIRPERSON GLANTZ: I just have one
3 clarifying question here. How do you get a breathing rate
4 for a fetus in the third trimester?

5 DR. BLAISDELL: We assumed that the fetus would
6 receive the same amount of air as the mother, so we used
7 the 16 to 30-year breathing rates. And that approach was
8 used throughout the document. It's a simplification,
9 because obviously the fetus doesn't necessarily receive
10 the same dose as the mother. But given the huge array of
11 chemicals and all that and the facts, it's a pretty short
12 period of time, it seemed like a reasonable assumption to
13 make.

14 ACTING CHAIRPERSON GLANTZ: So just to clarify --
15 because this is a question I had in reading the document.
16 So basically for the third trimester fetus, you're just
17 assuming for everything the same exposure levels as the
18 mother? I think you need to make that clear.

19 DR. BLAISDELL: On a per kilogram body weight
20 basis.

21 ACTING CHAIRPERSON GLANTZ: Go on. I'm sorry.

22 DR. DODGE: Okay. For clarification, our
23 previous values are in the last row there just for
24 comparison. In our previous document, we looked at zero
25 to nine and lifetime exposure, which was zero to 70.

1 --o0o--

2 DR. DODGE: These are the 95th percentile
3 breathing rates in liters per kilogram day.

4 The one thing I'd like to point out is that in
5 the zero to two-year column, we have quite a range in
6 breathing rates when looking at the three methods. For
7 example, comparing the met approach and DLW approach, we
8 have nearly a two-fold difference. But when you look at
9 the adults column at the far right, the numbers are pretty
10 close to the same for all three methods. And this
11 reflects the fact that there is a lot more information
12 there for adults as opposed to infants.

13 --o0o--

14 DR. DODGE: So there really is no gold standard
15 method among the three we present here for breathing rates
16 representative of the population. Each method has its
17 advantages and disadvantages.

18 What we ultimately chose to do is average the
19 CSFII or food intake study with the doubly labeled water
20 study to get our breathing rates. This is because we had
21 the individual or raw data to develop distributions
22 specific to the age groups that we're interested in.

23 And we used a Monte Carlo simulation to combine
24 the data and develop a stochastic distribution of
25 breathing rates.

1 breathing rates for SB 352 purposes. Again, this is just
2 for schools. And this is also based on U.S. EPA minute
3 ventilation rates. And we have sedentary, light,
4 moderate, and high intensity activities here.

5 So this represents breathing rates over a
6 one-hour period. And we expect these tables to be used to
7 customize breathing rates depending what the children are
8 doing during school hours or the hour that's of interest
9 in order to determine an exposure assessment.

10 Now, sedentary and passive activities, that
11 generally reflects students in a classroom sitting and
12 listening to the teacher or reading, for instance.

13 Moderate intensity, that would be PE or recess
14 activities. Now, we include high intensity here because
15 it's conceivable that, for example, after-school sports
16 will involve up to one hour of high intensity activities
17 perhaps like running events or football.

18 --o0o--

19 DR. DODGE: Chapter 4 is soil ingestion. This is
20 mostly soil or incidental soil ingestion. And it could
21 involve hand to mouth activities as well, especially for
22 children who may have soil on their hand and then put
23 their hand in their mouth.

24 Now, the values we use here for soil ingestion
25 rates are the same ones that U.S. EPA developed in their

1 Child-Specific Exposure Hand Factors Handbook of 2008.
2 And this approach is based on nine peer reviewed studies.
3 So we recommend basically the same thing that U.S. EPA
4 has.

5 Now, we don't have body weight data from these
6 individual studies. Therefore, we use age-specific body
7 weight recommendations that we have in Chapter 10 in order
8 to provide soil ingestion rates in terms of milligrams per
9 kilogram body weight per day.

10 Also data on variability was insufficient to
11 recommend a distribution for stochastic analysis so we
12 just have point estimates.

13 --o0o--

14 DR. DODGE: And these are the proposed point
15 estimates for soil ingestion rates. In our previous
16 document, we just had means. So new to this, our proposed
17 document here, is we added 95th percentiles.

18 --o0o--

19 DR. DODGE: Chapter 5, mother's milk pathway. In
20 our previous document, we just had two chemicals that are
21 known to accumulate in mother's milk. And those were
22 dioxins and furans and polychlorinated biphenyl, or PCBs.
23 In this revised version, we have added polycyclic aromatic
24 hydrocarbons, or PAHs, and lead to this short list of
25 chemicals to be evaluated by the mother's milk pathway.

1 In addition, in our revisions, we have updated
2 the mother's milk pathway model for dioxins and furans and
3 PCBs.

4 And finally, we re-evaluated intake rates for
5 breast fed infants. However, this change is very small
6 from our previous recommendations.

7 --o0o--

8 DR. DODGE: Chapter 6 is dermal exposure. And
9 this refers to contaminated soil and direct exposure onto
10 the skin.

11 Now, in our previous document, we have quite a
12 few variants in the dermal dose equation. We have average
13 concentration of chemical and soil. We have surface area
14 of exposed skin in square meters. We have soil loading
15 onto the skin in grams soil per square meter per day. We
16 have exposure frequency days per year; the ABS, which is a
17 fraction of chemical absorbed across skin. Exposure
18 duration, body weight averaging time to assess
19 carcinogenic risk.

20 So what we did differently in this go around --

21 --o0o--

22 DR. DODGE: -- is that we proposed combining
23 several of these variants into one overall variant called
24 the annual dermal load, or ADL, which is expressed in
25 milligrams soil per kilogram body weight per year. The

1 ADL combines the body surface area over body weight, soil
2 loading, the percent surface area exposed and exposure
3 frequency variants.

4 --o0o--

5 DR. DODGE: So the advantages in doing this sort
6 of combining of the variants into the ADL is that the high
7 end of the three variants combined, instead of using one
8 high end from each multiplied together, gives us a better
9 estimate of the variability. It's basically the proper
10 method for estimating overall variability from several
11 sources.

12 The distributional information that was
13 previously separate is now integrated in one distribution,
14 which simplifies the calculation for risk assessors.

15 --o0o--

16 DR. DODGE: In addition, new to this document, is
17 we divided California into three climate regions for
18 development of the ADLs into warm, mixed, and cold
19 climates.

20 Now, the reason we did this is because we had
21 information on exposure frequency and percent area of skin
22 exposed based on climate, whether a person was in a warm
23 or cold climate.

24 So for warm climates, we're talking about areas
25 that may have warm weather throughout the year, such as

1 the L.A. basin. Mixed climates would be hot summers, cold
2 winters, such as the Central Valley mountain regions. And
3 cold climates would be coastal areas such as
4 San Francisco, Eureka. However, districts should be
5 consulted concerning appropriate ADLs for a particular
6 location.

7 --o0o--

8 DR. DODGE: So this is our annual dermal load
9 table. I just wanted to point out in warm climates the
10 numbers are going to be higher versus cold climates it's
11 going to be a little bit lower. Their annual dermal load
12 is in units of grams soil per kilogram body weight per
13 year.

14 --o0o--

15 DR. DODGE: One other thing we did in this
16 chapter on dermal exposure assessment is that we updated
17 our dermal absorption factors. Again, dermal absorption
18 is expressed as a percent or fraction of the chemical
19 absorbed across skin from the soil. So we reviewed the
20 chemicals specific dermal absorption data that's out there
21 in the literature. In doing so, it takes into account
22 soil type, hydrophilicity of the chemical, soil, organic
23 content, and soil aging of the chemicals and soil time on
24 skin.

25 And for the dermal absorption factors, we didn't

1 have a lot of changes in many of the chemicals from our
2 previous document. A few increased, such as led went from
3 one percent to three percent. A few decreased. Mercury,
4 for instance, went from ten percent to four percent. And
5 others remained the same. For example, PCBs remained at
6 14 percent. PAHs remained at 13 percent.

7 --o0o--

8 MR. BLAISDELL: We're going to switch here.

9 Chapter 7 is home-raised consumption rates,
10 home-raised produce, meat, milk, and eggs. We used data
11 from the 1999-2000 NHNES data set to estimate consumption
12 rates for leafy, exposed, protected, and root vegetables
13 and fruits, home-raised chicken, beef, pork, eggs, and
14 cow's milk.

15 The NHNES collected data for one day, therefore,
16 typical intakes for individuals may not be captured.
17 Thereby, the upper percentiles and lower percentiles are
18 likely to be overestimated.

19 We determined faith in transport parameters for
20 determining food concentrations such as root uptake
21 factors, things like how much soil a pig eats and a whole
22 bunch of things that you may not want to know about.

23 --o0o--

24 MR. BLAISDELL: Next slide, the next chapter is
25 Chapter 8, which is water consumption. The Hot Spots

1 Program includes a surface water drinking pathway. So
2 far, this pathway has not been used in a hot spots risk
3 assessment, but it is available if it's needed.

4 The data from the U.S. EPA's Office of Water 2004
5 and U.S. EPA's Child-Specific Exposure Factors Handbook
6 were combined for various age ranges.

7 --o0o--

8 MR. BLAISDELL: Here are proposed water
9 consumption rates for the third trimester through age 70
10 for the mean and the 95th percentiles. They also have
11 distributions available.

12 --o0o-

13 DR. DODGE: Back over to me here.

14 Chapter 9 is fish consumption. This is
15 angler-caught fish.

16 I think we have a slide missing, but I'll go
17 ahead and do this. This is the first slide of the
18 chapter.

19 Fish consumption rate is needed for assessment of
20 potential health risks to individuals consuming fish from
21 waters impacted by facility emissions.

22 In the Hot Spots Program, this is generally
23 limited to fresh water bodies, including lakes and ponds.
24 And this is because the semi-volatile or non-volatile
25 chemicals will deposit in these sources of surface waters

1 represents the fisherman catching their fish and bringing
2 it home to their families.

3 The previous values there are on the right, the
4 last column, the nine-year scenario. That's what we used
5 before, and that was based on the Santa Monica study. You
6 can make a comparison to what we're proposing for the two
7 to nine year group. If you look at the bottom rows there
8 in consumption rates of grams per kilogram body weight per
9 day, the numbers are fairly close -- well, in fact, based
10 on the study that we're proposing, the consumption rates
11 are slightly less, but not too much there.

12 --o0o--

13 DR. DODGE: This is a table of our consumption
14 rates for adults. Again, the last column there on the
15 right is our previous values. And you can make a
16 comparison to the values we're proposing. The values
17 we're proposing are slightly less than what we had
18 previous.

19 --o0o--

20 DR. DODGE: Chapter 10 is body weights. Now,
21 most variants in our exposure document already incorporate
22 body weight into the analysis. But in a few cases, such
23 as fish consumption and soil intake, body weight
24 information was not provided, so we needed the body weight
25 variant. That was specific to the age groups we were

1 looking at.

2 The key study we used for body weights is the
3 National Health and Nutrition Examination Surveys,
4 otherwise known as NHNES. This is the most current
5 information on body weight for the U.S. population, and
6 it's been a continuous survey since 1999, being updated
7 roughly every two years or so.

8 --o0o--

9 DR. DODGE: These are the means that we're
10 proposing based on our age groups. And again, over on the
11 right-hand side the last column, those are our previous
12 values.

13 So I'll turn this over to Bob to finish up.

14 DR. BLAISDELL: As you can see, the population is
15 getting heavier.

16 --o0o--

17 DR. BLAISDELL: Chapter 11 contains information
18 on a variety of topics, including: Residential exposure
19 duration -- essentially how long people live in their
20 houses, time at home for residents, and exposure duration
21 for off-site workers. It also contains a discussion of
22 individual versus population risk.

23 --o0o--

24 DR. BLAISDELL: We're proposing a 30-year
25 exposure -- residency exposure duration, which is around

1 the 90 or 95th percentile for residence time. The data
2 were obtained on California residency time from the
3 American Community Surveys. The California data are
4 generally consistent with nationwide data.

5 We're also recommending that a nine-year and
6 70-year scenario be included. And the nine year is
7 approximately the mean of residency time and 70 years
8 would represent a lifetime residency exposure duration.

9 --o0o--

10 DR. BLAISDELL: Worker exposure duration. Risk
11 to off-site workers near a facility is included in the Hot
12 Spots Program. Risk to off-site workers is evaluated
13 using the same health values as for the public.

14 In other words, we don't use occupational health
15 values, which are generally higher. Workers that are
16 actually employed at the facility being evaluated are
17 covered by Cal OSHA using occupational health standards.
18 The length of time that a worker is on the job with a
19 specific employer, i.e., job tenure, determines the
20 exposure duration.

21 PANEL MEMBER FROINES: Why is it the length of
22 time that is on job with a specific employer? I've been a
23 chemist for 50 years.

24 DR. BLAISDELL: Well, John, the Hot Spots Program
25 looks at the risks from emissions from a particular

1 facility. So you can be a chemist all your life, but
2 we're only looking at an individual facility. So if you
3 changed jobs and move off to another facility and also to
4 do chemistry, we wouldn't consider that time. That's
5 basically part of the legislation.

6 --o0o--

7 DR. BLAISDELL: Worker exposure durations key
8 study. This is a Census Bureau Survey of income and
9 program participation.

10 The SIPP, the SIPP sample is a
11 multi-stage-stratified sample of the U.S. civilian
12 non-institutionalized population. Workers are asked when
13 they started working for a current or most recent past
14 employer and when they stopped working for that same
15 employer. This is an absolutely ideal data for what we
16 want to do. Ideally, you'd have longitudinal data on
17 individual workers, but it is the best available.

18 The current job definition your data covers 1996
19 through 2008. And obviously, in this kind of economy,
20 these things can change over time.

21 --o0o--

22 DR. BLAISDELL: Previous OEHHA recommendation,
23 which I believe was the same that U.S. EPA used in some of
24 their programs, is 40 years for employment tenure. We're
25 proposing to use 25 years for employment exposure

1 duration. It represents a reasonable estimate of the 95th
2 percentile of employment duration from the SIPP.

3 The study is supported by less rigorous surveys
4 that ask questions regarding length of employment with a
5 specific employer.

6 --o0o--

7 DR. BLAISDELL: Individual versus population
8 risk. In this version of the document, we wanted to more
9 clearly separate out the concept of individual and
10 population risk. In the previous version, we were
11 recommending a 70-year exposure duration, which sort of
12 mixes two concepts: Population and individual risk
13 together.

14 In the previous version, we also assumed that the
15 residential maximally exposed individual is exposed
16 24 hours a day, seven days a week, 365 days a year to
17 facility emissions at the maximum impact point, which
18 there is a certain amount of -- it's not incredibly
19 realistic in terms of typical exposure.

20 One of the issues with individual versus
21 population risk is that a small Facility A may have a
22 small zone of impact. In other words, a dry cleaner or a
23 gas station where few people are impacted at relatively
24 high cancer risk, and the risk will drop off pretty
25 rapidly around these facilities.

1 In these circumstances, the individual risk is
2 above acceptable limits and risk management is triggered,
3 which is appropriate. However, you can also have a large
4 facility with extensive but diluted emissions. Maybe the
5 facility has many, many stacks or a lot of the emissions
6 are area source emissions and can have a huge footprint.
7 Thousands of people can be impacted. But because the
8 emissions are diluted, the risk is below the triggers for
9 individual risk and risk management would not be
10 triggered.

11 --o0o--

12 DR. BLAISDELL: In the past, risk assessments
13 have recorded a cancer burden, which was simply the number
14 of people exposed times the cancer risk, which this would
15 often come out to be .4 something and weren't intuitively
16 obvious to the general public.

17 OEHHA recognizes a need for more focus on the
18 population applied risk to capture the example where many
19 people are exposed to an acceptable cancer risk, say, in
20 the 1 times 10 to the -6 range.

21 We recommend reporting the number of people
22 exposed within the cancer isopleths to 10 to the -6 and
23 higher to give a clearer indication of the population-wide
24 health impacts from facility emissions.

25 --o0o--

1 DR. BLAISDELL: Activity patterns.

2 Previous exposure to the residential MEI, as I
3 mentioned earlier, was assumed to be 24 hours a day, 365
4 days -- actually, I think we gave people two weeks off for
5 vacation. But for 70 years.

6 And the Air Resource Board and OEHHA looked at
7 some survey data to try to see if we can come up with some
8 information on the fraction of the time that was spent at
9 home. And we also -- in these estimates, vacation is also
10 included. So the data indicate that about 85 percent of
11 your time is spent at home between ages zero to two. And
12 essentially 72 to 73 percent of your time from ages 2 to
13 16 and 16 to 70.

14 One of the issues with considering time away from
15 residence is that it's not known where the person is when
16 they are away and therefore, if the person was still
17 exposed to facility -- significant facility emissions.

18 In other words, if you're just going down the
19 street to school or the place where you work is located
20 within the isopleth of a really large facility, it may not
21 do you much good to leave for work or school.

22 For the purposes of estimating cancer risk from a
23 specific facility, we're recommending that there is no
24 exposure from the facility when you're away from the
25 residence, unless there is a school within the 1 times 10

1 the -6 isopleth. That would generally be an indication
2 that the facility was large and potential for exposure to
3 children.

4 Again, this is part of trying to come up with
5 some more accurate ways of estimating individual risk and
6 clearly separating out the concepts of individual risk and
7 population risk.

8 --o0o--

9 DR. BLAISDELL: And now the summary. The updated
10 draft exposure assessment guidelines incorporates new data
11 on exposure parameters, including transport published
12 after the 2000 version. It updates the air dispersion
13 modeling, including -- and includes an option for spatial
14 averaging. The age ranges for exposure variants
15 accommodate the assessment of the greater risk from early
16 in life exposure to carcinogens. We're attempting to
17 emphasize population risk more. And the residential and
18 worker exposure duration are based on newer data.

19 Thank you for your attention.

20 ACTING CHAIRPERSON GLANTZ: Okay. Do you want to
21 say anything, Melanie?

22 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

23 MARTY: Yeah. I just want to say we do have some slides
24 on the public comments in our responses. So I don't know
25 if you want to hear them or see them or you want to wait a

1 little bit.

2 ACTING CHAIRPERSON GLANTZ: Why don't you go
3 through those?

4 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
5 MARTY: Take five so we can get that presentation up.

6 ACTING CHAIRPERSON GLANTZ: While they're getting
7 the presentation together, what I would suggest -- I know
8 we've been sitting here a long time, but it is also a long
9 report.

10 And I mean, I think we have two options. One is
11 to take a break after OEHHA finishes, but it is kind of
12 lunch time. We could break for lunch. Or what I would
13 suggest is that we go until, say, 12:00 to actually start
14 the discussion. Go until 12:30 and then just break for
15 lunch for however long we decide so we can get -- because
16 I think it's going to be -- I mean, I think the report is
17 pretty good, but I think there are issues to discuss. And
18 I want to have adequate time.

19 So are people willing -- I know it's a long time
20 to sit, but are you willing to do that, go to 12:30 and
21 then we'll break for lunch? Okay.

22 PANEL MEMBER FROINES: I'm concerned about the
23 reporter. We always take breaks so he has a chance --

24 ACTING CHAIRPERSON GLANTZ: It's a she. She's
25 fine.

1 So I think everybody else thinks we should go
2 until 12:00. So it's not that much longer. But I'm
3 afraid there is no such thing as a short break at a
4 meeting like this. Are you guys ready to go there? We're
5 going to go until 12:30 and then we'll break for lunch.

6 Okay. There were not a lot of public comments,
7 so this should go pretty quickly.

8 DR. BLAISDELL: This is a short presentation of
9 our of the public comments that we received and OEHHA's
10 response to those comments.

11 We received comments from the Santa Barbara Air
12 Pollution Control District, the Western States Petroleum
13 Association, otherwise known as WSPA; the County
14 Sanitation Districts of Los Angeles County; the Natural
15 Resource Defense Council, NRDC; and the U.S. Environmental
16 Protection Agency, U.S. EPA.

17 This presentation summarizes the significant
18 comments of general interest. We have a much more
19 detailed Response to Comments posted on OEHHA's website.

20 ACTING CHAIRPERSON GLANTZ: And all the members
21 got the Response to Comments, too; right?

22 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
23 MARTY: Yes.

24 DR. BLAISDELL: These are the comments from the
25 Santa Barbara Air Pollution Control District. A comment

1 different from the previous breathing rates to the limited
2 extent that they can be compared.

3 --o0o--

4 DR. BLAISDELL: These are comments from NRDC.

5 The NRDC urges OEHHA to encourage presentation of
6 risks from multiple facilities.

7 We agree that cumulative risks from multiple
8 facilities is important, and we actually have a document
9 on our website that addresses cumulative risks. But the
10 Hot Spots legislation specifies that hot spots risk
11 assessments only consider emissions from the facility in
12 question. The HARP Program actually can do multiple
13 facilities if people are interested in doing that.

14 --o0o--

15 PANEL MEMBER FROINES: Cumulative risk issues are
16 very important and very badly dealt with generally.

17 DR. BLAISDELL: The NRDC is concerned that daily
18 or yearly variability in emissions could lead to a
19 significant underestimation of exposure. NRDC is
20 particularly concerned with persistent and/or
21 bioaccumulative contaminants. Long-term exposure
22 estimates based solely on annual averages could
23 significantly underestimate parameters.

24 And our response is that estimation of the
25 variability in hourly emissions from industrial process is

1 not generally available. However, if the annual average
2 emission rate is properly determined, estimates of cancer
3 and non-cancer chronic risk would probably not be
4 underestimated, even with bio accumulative contaminants.

5 --o0o--

6 DR. BLAISDELL: The estimates of acute maximum
7 one-hour concentrations consider worst-case one-hour
8 emissions where appropriate. For some types of
9 facilities, we get start-up conditions and that sort of
10 thing.

11 Emission estimates are intended to er on the side
12 of over-estimation, not under-estimation. However, if the
13 emissions estimates are inaccurate, the risk estimates
14 could be seriously underestimated.

15 --o0o--

16 DR. BLAISDELL: The list of contaminants for
17 which this mother's milk pathway is to be evaluated does
18 not include all air toxics for which there is evidence of
19 exposure through breast milk ingestion. Inhalation
20 exposure to volatile organic compounds, including Benzene,
21 Toluene, and Tetrachloroethylene has been found to result
22 in elevated levels of these compounds in breast milk.

23 --o0o--

24 DR. BLAISDELL: We actually took a look at this
25 issue and determined that the exposure to the breast milk

1 pathway through volatile organic chemicals was pretty
2 insignificant relative to the infant's exposure to
3 inhalation. And the inhalation pathway would be assessed
4 for the 30 years of that infant's -- first 30 years of
5 that infant's life. So it does tend to swamp out the
6 small amount they get through the breast milk pathway.

7 The chemicals of most concern for the breast milk
8 pathway with low level environmental parameters are those
9 with a long half-life in the mother's body that accumulate
10 in the mother's body, such as dioxins that accumulate and
11 fat. And they're very slowly eliminated.

12 --o0o--

13 DR. BLAISDELL: These are the comments of Western
14 States Petroleum Association. They say, "We support the
15 proposed changes to the default values for exposure
16 duration for the residential and worker. As noted in the
17 TSD, a 30-year residential exposure duration is a
18 reasonable estimate of the 90th or 95 percentile of
19 resident's time. Similarly, for the workers, 25 years
20 represents a reasonable estimate of the 95 percentile, and
21 these proposed values are consistent with default values
22 used in other regulatory programs."

23 --o0o--

24 DR. BLAISDELL: And essentially, we were pleased
25 that there is availability on these parameters of

1 employment duration and activity patterns and exposure
2 duration which allowed us to refine our exposure model.

3 --o0o--

4 DR. BLAISDELL: The derivation of breathing rate
5 point estimates to be applied for exposures of less than
6 24 hours per day -- for example, the eight hours is
7 unclear. It's also unclear how to translate a one-hour
8 breathing rate to an eight-hour or other exposure time,
9 breathing rate for a school child, off-site worker, or
10 other receptor.

11 We have clarified the application of the
12 breathing rates for the off-site workers in Chapter 3.
13 OEHHA has added -- actually that should be moderate.
14 We've added heavy intensity and light intensity of
15 breathing rates so that a greater range of worker
16 breathing rates are available for different options. I
17 think we added the moderate.

18 --o0o--

19 DR. BLAISDELL: It's well documented that outdoor
20 air is not -- well, the concentration of outdoor air is
21 not well correlated with indoor air, at least based on
22 centralized ambient air monitors and is very poorly
23 correlated with personal exposure.

24 Indeed, indoor air quality is a function of
25 ventilation, such as open windows, air conditioner use,

1 thing is true for the 95th percentiles.

2 Our response is that we agree that it's
3 physiologically implausible that the high end 95
4 percentile breathing rates on a per kilogram body weight
5 basis would be higher than in the age 0 to 2 group
6 compared to the 2 to 9. I'm sorry.

7 --o0o--

8 DR. BLAISDELL: Our response, the choleric intake
9 method will tend to overestimate breathing rate because it
10 does not capture typical choleric intake with only two
11 days worth of survey data. In other words, it's not
12 longitudinal data on each individual.

13 We took another look at this, and the met method
14 is less certain than the other two methods because of the
15 upper percentiles exceed the limits of sustainable
16 activities, and also the body weight data was not on the
17 same individuals as the activity data.

18 We re-evaluated our approach and decided in the
19 interest of a consistent approach for each age group to
20 average the doubly labeled water method and the total
21 choleric intake CSFII method for all age groups, including
22 the 0 to 2 years, and not the average in the met method,
23 which has more uncertainty than other methods.

24 And this concludes our presentation.

25 ACTING CHAIRPERSON GLANTZ: Melanie, did you want

1 to add anything else?

2 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

3 MARTY: No. Just one little quick point. I'm not sure it
4 was totally clear in our response, but the concern about
5 indoor air measured concentrations being different than
6 outdoor air, yes, everybody recognizes that. But the
7 comment alluded to central site monitors, and that's not
8 the data we're using. We're using air dispersion modeling
9 from a specific facility that is near to the residential
10 or off-site worker receptor. So it's not quite the same
11 thing.

12 And we actually do have a few facilities where
13 indoor air measures of specific chemicals were pretty well
14 correlated with the sites around them. So the sources of
15 emissions around them. So we didn't think it was -- for
16 our purposes, yes, we all recognize that changes happen in
17 indoor air. You use cleaning products. There's building
18 materials off-gassing, but we're looking at the risk from
19 the specific facility.

20 ACTING CHAIRPERSON GLANTZ: Okay. Well, what I
21 would propose -- and so again, we'll go for about another
22 25, 30 minutes. The court reporter is smiling. So what I
23 would suggest, this is a long, complicated report. I have
24 just a couple comments.

25 First of all, I think we can predict with

1 reasonable probability that we are not going to vote on
2 this report today, especially since a few important people
3 aren't here.

4 So I would ask the Panel in making your comments
5 if you have relatively minor points or small corrections
6 to just give them to Melanie and not -- I don't think we
7 need to talk about them here, because this report will be
8 coming back at least one more time.

9 And then the second thing that I would suggest is
10 that we go through the report a chapter at a time and get
11 people's comments on each of the chapters, starting with
12 Chapter 2 and then come back and talk about sort of the
13 global issues and the introduction last.

14 Is that okay with people?

15 PANEL MEMBER NAZAROFF: A few of the comments I
16 have are overarching.

17 ACTING CHAIRPERSON GLANTZ: Do you want to start
18 with that?

19 PANEL MEMBER NAZAROFF: Sure. We could do that.

20 ACTING CHAIRPERSON GLANTZ: Is that okay?

21 PANEL MEMBER FROINES: Stan?

22 ACTING CHAIRPERSON GLANTZ: Yes, John.

23 PANEL MEMBER FROINES: I couldn't tell who was
24 speaking.

25 PANEL MEMBER NAZAROFF: Sorry, John. It's Bill.

1 ACTING CHAIRPERSON GLANTZ: Bill Nazaroff.

2 PANEL MEMBER FROINES: Thank you.

3 ACTING CHAIRPERSON GLANTZ: If you want, why
4 don't we start -- that was the other alternative. So why
5 don't we start with the sort of discussion of the broader
6 issues raised in the report. And then after we do that,
7 we'll try to go through and focus on specifics. Is that
8 okay? I just think mixing them will really lead to kind
9 of a confused conversation, I think. So why don't you go
10 ahead.

11 PANEL MEMBER NAZAROFF: Okay. Thank you.

12 So I think then what I'd like to do is to provide
13 some overall comments now. I've sent to Melanie just this
14 morning just in time for the Committee work my full set of
15 comments, which numbered 47, about a third of them I want
16 to call out. I'll only highlight the first several now
17 and then the rest are tied to specific chapters.

18 Of course, this is an impressive document in both
19 scope and depth. And in reading it, I really was trying
20 to focus on three main points.

21 First is what is done is what is reported here
22 done correctly.

23 Second, what is missing? Are there blind spots
24 that lie within the purview of the hot spots mandate and
25 SB 32 and are just not addressed. I mean, not addressed

1 effectively or at all.

2 And third, how might the document itself be
3 improved as guidance. And so in terms of the overarching
4 or general comments, one overall one is that I'm missing
5 in our -- in what's presented to us the evidence from the
6 field. What kind of feedback does OEHHA have, does ARB
7 have? How is that feedback being used to help shape this
8 guidance document? This is a different time than when the
9 document was first put together. You have ten years of
10 experience of the document being used. It's part of a
11 control system. The control systems need feedback in
12 order to be operating effectively. That may be happening.
13 We're not seeing it. If it's not happening, it needs to
14 happen. If it's happening and we're not seeing it, maybe
15 that's okay. But it was a concern to me as I read this.

16 And let me just continue with a few more points
17 rather than interjecting with discussion here. I have a
18 bit of a concern or suggestion say for the general
19 presentation style. I liked the layout in terms of
20 chapter by chapter coverage and appendices that go into
21 more details. But within the chapters, I really was
22 looking for something that was closer to the way that the
23 chemical identification report works where there is a very
24 clear conclusion at the beginning. The set of
25 recommendations was presented at the beginning of the

1 chapter, and then if you want to see all the details --

2 ACTING CHAIRPERSON GLANTZ: Just for the record,
3 I didn't put him up to suggesting that.

4 PANEL MEMBER NAZAROFF: Where I hit that more
5 acutely than anywhere else was on breathing rates. I had
6 to wade through -- and I couldn't tell where I was going
7 to get to a lot of text and a lot of tables. I finally
8 came to something that said EPA's recommended breathing
9 rates, but that wasn't OEHHA's breathing rates. And the
10 text referred to these recommended breathing rates. And I
11 had to read a few more pages. Anyway, you get the broad
12 point. And I think every chapter would benefit, the
13 reader would benefit from having what it is you're
14 recommending in the end put right up front and then
15 support it afterward.

16 Third point, I struggle -- and this is a comment
17 and not a suggestion. But I struggle with the imbalance
18 in the levels of attention and precision. It felt to me
19 like there is a real need to do a sensitivity analysis of
20 the overall exercise, because we get a contrast between
21 some data that are input parameters that have an
22 exquisitely rich empirical basis for -- we get reporting
23 with five significant figures in some places. The
24 significant figure police have to go through this document
25 to kind of dial back on where it's gotten out of control.

1 That's a small side point.

2 The broader point is that there are other key
3 aspects of the guidance where there is one sentence that
4 declares what's being done without adequate support for
5 that declaration. Specific example of that is in the
6 treatment of the age -- I've forgotten what you've called
7 them. The age adjustment factors for connecting exposure
8 to risk, factor of ten for young children, factor of three
9 for some other group. If that's 10 or 20 or 5 in that
10 first group, that makes more difference than any of the
11 detail about how breathing rate is being handled. There
12 was a reference I found it --

13 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

14 MARTY: Bill, this panel reviewed a giant document just on
15 that in 2000.

16 PANEL MEMBER NAZAROFF: But the reference in this
17 document to that document I typed in the URL in my
18 computer and I got "document doesn't exist" or couldn't
19 find it. So, you know, a little bit more needs to be done
20 here to connect that mammoth document to what's presented
21 in this location.

22 And it's a broader comment than that one specific
23 point. And that is just -- and again, this is a comment
24 and not a suggestion in this respect that I don't know how
25 to reconcile the parts of this problem that we can do with

1 exquisite precision. And should we continue to, like,
2 dive more deeply in when there are other key parts of this
3 problem that we can only say, you know, here is a factor
4 of ten or a factor of three that we're using to make an
5 adjustment. Some kind of rationalization of that, I'd
6 like to see us make some progress on.

7 I have one other thing I think I want to bring up
8 as a broad comment. Yeah, this goes to the sort of
9 whether there are blind spots or not. And I have a couple
10 that I think I've identified. So I just want to mention
11 one right now. There is a sentence -- so this concerns
12 dermal exposure and the dermal exposure pathway. The way
13 dermal exposure in this document is treated is that
14 contaminant is emitted into the air. It has to be either
15 semi-volatile or condensed phase species as a particulate
16 matter. Deposits onto soil. Can accumulate over time in
17 the soil. People come out and they play in the dirt or
18 they garden or they do whatever. They get dirt on their
19 hands. And then before they wash the dirt off their
20 hands, there is some transfer to the skin and it goes in.

21 And the thing I'm concerned about is that that is
22 a narrow view of what dermal pathways might look like.
23 There is a sentence to sort of justify this approach that
24 I think is quite important. It shows up in Chapter 6, the
25 first page of Chapter 6. But it's unsubstantiated, and I

1 don't believe it. The sentence says, "Although dermal
2 exposure to volatile chemicals can be significant with the
3 high air concentrations found in industrial settings, this
4 pathway is not a significant exposure source for lower
5 environmental air concentrations, both relative to other
6 exposure pathways and in terms of the magnitude of the
7 dermal dose."

8 It's increasingly known that chemicals that have
9 this property known as amphiphilicity -- I had to look
10 this up. Somebody taught me this word a few years ago.
11 It's chemicals that have both lipophilic character but
12 also a hydrophilic character because of the functional
13 groups, that those actually have pretty good trans-dermal
14 permeation potential and will readily partition from the
15 air into skin surface oils.

16 And the choke point then for dermal uptake
17 directly from the air may be a lesser resistance than
18 having to go through our inhaling air in order to get lung
19 exposure. I think there are important volatile and
20 semi-volatile parameters that are trans-dermal, that occur
21 from environmental encounters with these species and that
22 ought to be included in an aggregate exposure assessment
23 or at least carefully looked at and demonstrated that they
24 aren't important. I don't find the sentence does that.

25 Those are my general comments. Thank you.

1 PANEL MEMBER GILL: I have two general comments.
2 Actually, the document is very --

3 ACTING CHAIRPERSON GLANTZ: Sorry, Sarjeet Gill,
4 for John.

5 PANEL MEMBER GILL: This document is rather
6 extensive. Reading this was a task.

7 I would say, for example, one of the things is
8 actually -- Bill has already talked about summary actually
9 would be an ideal thing to do. But I want to go further
10 and say what you need to do is based on your experience in
11 the past how has this document effected implementation.
12 And give examples of if this is a scenario, how would this
13 be implemented. Because that is example a lot of times
14 individuals in the comment section say how does it effect
15 us. How does it implement. I don't know whether it's
16 legally possible to do this, that if these other
17 concentrations are observed in a certain environment, how
18 would you be implementing those, given those examples.

19 You can take a real life example where you
20 implemented those, how would the new document effect that
21 implementation. And so that would be an example giving a
22 case study scenario that has been done. I don't know
23 whether you want to do it legally or not. So that is an
24 issue I think we need to address and see. If not, the
25 alternative is you can put up another scenario which is

1 not legally binding, but is a potential area that not
2 covers all aspects, but certain aspects of how a certain
3 particular part of the document will be implied. So it's
4 a bit more -- it's easier to read through some of the
5 details that is present in the document is relatively
6 difficult to read and talk about this implementation, for
7 example.

8 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

9 MARTY: Yeah, I should bring up that is -- well, there are
10 two things.

11 There is a guidance manual that gets produced by
12 ARB and OEHHA for people actually doing a risk assessment.
13 And the guidance manual exists right now, except for it's
14 got the old -- the 2000 version exposure parameters and
15 variants in there. So we can't produce that document
16 until we come to some agreement with the panel on this
17 document. So there is that.

18 And then Bob mentioned the HARP Program, which is
19 also waiting for this document to be done and then that
20 will be reprogrammed with the newer exposure variants.

21 So it's a little bit complicated to try to
22 compare what's going to happen with this new exposure
23 parameters for a whole bunch of reasons. That's a couple
24 of them.

25 The other issue is that for some of the

1 chemicals, the actual health values have changed. So some
2 of them have gone up. Some of them have gone down. It's
3 just really kind of a -- it's a really difficult
4 proposition to try to do what you're asking.

5 ACTING CHAIRPERSON GLANTZ: But I think -- I
6 mean, I did not put these people up to this. I mean, as
7 the lead, I've been talking to Melanie and the others
8 about this. I had a similar suggestion.

9 I do think though that it would really help, make
10 the document easy to understand if you could at least give
11 an example, you know, which could be -- I mean, I hadn't
12 thought of using a real one from the past with the updated
13 numbers or even one that was hypothetical, just to show
14 how all the pieces would fit together. I mean, that's
15 sort of what you're suggesting, right. Yeah. It would
16 really, really help to make the document comprehensive,
17 more comprehensible and to kind of put things into some
18 context. I mean, there wouldn't necessarily have to be
19 every little detail thing, but to just show how to reduce
20 the level of abstraction.

21 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

22 MARTY: We could do that probably by pathway. It would be
23 really hard to try to combine all the pathways and show a
24 difference, for example, for a multi-pathway chemical. We
25 can do calculation for an inhalation exposure to a

1 carcinogen. This is what it would have looked like using
2 previous --

3 ACTING CHAIRPERSON GLANTZ: No. No. I don't
4 think what's being suggested is to show how things have
5 changed. I don't think that's so important. I think the
6 thing is to just give an example of how the information in
7 the document would be used going forward. I don't think
8 you need to go back and compare it to the 2000 model. I'm
9 just saying -- maybe that was when we talked about this
10 earlier -- I don't think you need to say, well, the old
11 way led to this and the new way leads to that. I think it
12 should just say if you want to take this model and do a
13 comprehensive risk assessment of some kind of facility,
14 for example. Because if you look in the appendices, you
15 have some example air distribution models for different
16 things.

17 And I would say you could take one of those or a
18 couple of those and just say if you had one of these
19 example facilities from appendix whatever it was, then how
20 would you then use what's in here to do a risk assessment
21 for a hypothetical facility. I don't think he's
22 suggesting -- and I certainly wasn't suggesting that you
23 compare it to say how it's changed compared to the old
24 document. I mean, this is superseding the old document.
25 So I don't think you need to go back to that. I mean, is

1 that right?

2 PANEL MEMBER BUCKPITT: That's true.

3 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

4 MARTY: Well --

5 PANEL MEMBER GILL: That's true.

6 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

7 MARTY: That really awaits the reprogramming of HARP,
8 because you can't take all this data and crank out an
9 assessment without some software.

10 DR. BLAISDELL: Just programming all this in is
11 really pretty complicated.

12 ACTING CHAIRPERSON GLANTZ: Well, would it be
13 possible to sort of outline what the steps would be and
14 sort of which data would be used in that case, just to
15 give the thing something -- a kind of a more concrete
16 foundation to interpret the massive amount of detail.

17 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

18 MARTY: That's in the guidance manual. That's what the
19 guidance manual does. So we have the old guidance manual
20 from the previous document, and we have to update that to
21 reflect the newer information.

22 It may be useful to look at the old guidance
23 manual and see how it says. Because what we refer to it
24 as the cookbook, this is how you do a risk assessment.
25 And it's essentially condensing all of these technical

1 support documents into a how-to.

2 DR. BLAISDELL: It contains the health values.
3 It contains the algorithms --

4 ACTING CHAIRPERSON GLANTZ: I think we're
5 suggesting something simpler than that which is to just
6 take a -- not a general -- we're not saying write the
7 guidance manual now. But I think it would really help to
8 just take a for example if you had this, here's how you
9 would use what's in here in one specific case.

10 PANEL MEMBER GILL: The main issue that's going
11 to come up is what's the legality between this document
12 and how you implement the guidance manual. Okay. Because
13 that would be part of a legal issue. And I don't know
14 whether that is or not how you -- because if you suggest
15 this is an example, then it can be used as an example in a
16 legal situation that this is the case.

17 So that's why I'm suggesting is that you want to
18 be very general in your approach, but saying these are
19 some of the issues we need to look at. And that can be
20 put in a very simple format. Because a guidance manual I
21 assume would have much greater detail. Because how big
22 the guidance manual is, if this is a guidance manual it is
23 about a third of the thickness and it's too big in my
24 sense, because it actually -- you lose in all the details
25 you lose all the concepts that you have. That's what I'm

1 trying to get at.

2 DR. BLAISDELL: The guidance manual will actually
3 be pretty short, maybe 100 pages.

4 ACTING CHAIRPERSON GLANTZ: Do you have anything
5 else?

6 PANEL MEMBER GILL: No.

7 PANEL MEMBER BUCKPITT: I have a specific
8 comment.

9 ACTING CHAIRPERSON GLANTZ: Alan is talking now,
10 John.

11 PANEL MEMBER BUCKPITT: In this, I'm not sure
12 it's possible to do, but some discussion of internal dose.
13 I mean, we make the assumption that if you breathe more
14 rapidly that you take in more compound. But I don't think
15 those things are necessarily proportional. They're very
16 dependant sometimes on metabolism. They're dependent on
17 the exposure rates. The same would go to what Bill said
18 about skin absorption that's there for a few minutes.
19 It's the likelihood of penetration is going to be a lot
20 less, even though it's a detergent, as you pointed out.
21 I'm not sure we can do anything with those parts of the
22 equation, but I'm sure that they do contribute to the
23 internal dose and how much gets in.

24 ACTING CHAIRPERSON GLANTZ: So John, did you have
25 anything?

1 PANEL MEMBER FROINES: Can I ask Alan a question
2 based on what he said? Because I agree with him, and I
3 made some notes earlier to myself.

4 It seems to me that the whole issue of
5 toxicogenetics needs to be explicitly addressed. And that
6 I don't quite know how the easiest way that would be.

7 But the example of internal dose that he just
8 talked about is extremely important. And breathing rates
9 is -- and just looking at breathing rates is a vast
10 over-simplification of the issues. So I'm not sure how
11 one -- what to recommend. But it does seem to me that
12 Alan was right on target. So was Bill about the dermal
13 issue, which is -- I had to live with on the methyl iodide
14 case, where -- I won't go into it. But it was a major
15 issue.

16 DR. BLAISDELL: To the extent that we can in
17 terms of the pharmico genetics and pharmico dynamics,
18 they're taking into account in the dose response. In
19 other words, if we have an animal study and we're studying
20 humans, we will take into account internal dose. So it's
21 not really part of this document.

22 Some of these assumptions in terms of the percent
23 absorbed say for volatile organic chemicals when you're
24 inhaling it, we've simplified that. But there aren't a
25 lot of data often on these individual chemicals. And it

1 is -- if you're going to make -- if you're going to get
2 into that, then you have to have data on individual
3 chemicals.

4 ACTING CHAIRPERSON GLANTZ: Anything else?

5 John, did you have anything else?

6 PANEL MEMBER FROINES: Well, I think the comments
7 that have been made have been terrific. And I'll come
8 back later and take an opportunity to comment that I think
9 is necessary, but I think right now we can move ahead.

10 ACTING CHAIRPERSON GLANTZ: Okay.

11 PANEL MEMBER FROINES: But since you are the
12 lead, Stan, we normally would start out with the lead --

13 ACTING CHAIRPERSON GLANTZ: Right.

14 PANEL MEMBER FROINES: -- making the first
15 comments. And in this situation, it's backwards. So I
16 would be interested in hearing what your major comments
17 were.

18 ACTING CHAIRPERSON GLANTZ: Well, I just decided
19 we could do things backwards today. Basically, my major
20 comments have been made.

21 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

22 MARTY: Does that mean you'll approve the document first
23 and then we'll talk about it?

24 ACTING CHAIRPERSON GLANTZ: No.

25 (Laughter)

1 ACTING CHAIRPERSON GLANTZ: No, I think, as I
2 commented to Melanie about, I didn't put anybody up to
3 saying the things they said. I mean, I think my major
4 comments have been -- on the document as a whole been
5 made.

6 The one other major comment that I had -- which
7 has already been partially addressed in her revision of
8 the document -- is I think that there needs to be more
9 discussion of the logic behind the different tiers and
10 when you would use which tier.

11 And as you noticed, you probably didn't look at
12 it in the document until recently, but there was some --
13 they sent you a rewritten Chapter 1 that spelled that out
14 a little bit more. That was my one other comment. I
15 still think that needs a little more work.

16 And the other thing, which was I thought clear in
17 the presentation at the end, but I didn't think was very
18 clear in the document is this issue between the most
19 exposed individual versus a large area source where you
20 have a lot of people exposed maybe at lower levels. And
21 it still isn't totally clear to me which of those two
22 approaches ought to be used in a specific situation. It
23 was a little clearer in the presentation, but that was a
24 question I had when I finished reading the document, which
25 I don't think I mentioned before.

1 And then the other thing about this issue about
2 handling the fetal exposures as being treated as paternal
3 exposures I didn't see anywhere in the document. It may
4 have been in there somewhere, but I missed that.

5 But otherwise, I just agree with what everybody
6 else said. So anyway, so it's 12:31. I think we came
7 pretty close. So I think this is sort of a logical place
8 to break. And when we come back, I think we should go
9 through it a chapter at a time and get specific comments
10 on the chapters.

11 I guess the question is where can we eat and how
12 short a break could we take? Because I'm concerned that
13 we're going to run out of time because it is such a long
14 document. So is there any place in the building to eat or
15 nearby? There is a cafe in the building.

16 Is a half hour too short? Forty-five minutes?
17 Because I'm very concerned we're going to run out of time.
18 Is that okay with people?

19 PANEL MEMBER FROINES: Forty-five minutes you
20 say?

21 ACTING CHAIRPERSON GLANTZ: Forty-five minutes.
22 So we will reconvene at a quarter after 1:00 California
23 time. And I hope you can find a place to eat there in
24 Colorado, John.

25 PANEL MEMBER FROINES: The problem is the place

1 that Peter arranged for me to sit in this room, there
2 is -- it's outside of town and there is nothing within any
3 perceivable distance. I need more time or less time, but
4 I'll live with it.

5 ACTING CHAIRPERSON GLANTZ: Okay. We'll
6 reconvene at a quarter after 1:00. Thank you everybody.

7 (Whereupon the Panel recessed for lunch at
8 12:33 PM)

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 ACTING CHAIRPERSON GLANTZ: Well, do people want
2 to talk about that first?

3 PANEL MEMBER BUCKPITT: That's the only reason I
4 brought that up before we do the other.

5 ACTING CHAIRPERSON GLANTZ: Let's do that then.
6 Let's let Melanie talk, and then we'll do the body weight
7 then and then we'll go back.

8 PANEL MEMBER BUCKPITT: But that may not be
9 accurate.

10 DR. BLAISDELL: I think --

11 ACTING CHAIRPERSON GLANTZ: Let's let --

12 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

13 MARTY: Can we start with the general stuff?

14 ACTING CHAIRPERSON GLANTZ: Let Melanie deal with
15 the general stuff. And then we'll do body weight and then
16 go back and start with Chapter 2.

17 Go ahead, Melanie.

18 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

19 MARTY: Okay. So Bill brought up some general points I
20 just thought I would respond to a little bit here anyway.

21 So one is how has feedback shaped the document?
22 And since that methodology has been out there for
23 ten years now and the various sundry facilities have used
24 it and risk assessments. Just so everyone is clear, when
25 we generated this document, it went to the Air Resources

1 Board for review. And in fact, they generated Chapter 2
2 because we are not air dispersion modeling experts.

3 And also the California Association -- CAPOCA --
4 California Air Pollution Control Officers Association for
5 their review -- and that's very recent. Prior to that, we
6 were hearing from the air districts and the Air Board and
7 even some of the facilities about areas that they thought
8 were problematic and so have attempted to address those
9 areas. And those are primarily the maximally exposed
10 individual being exposed to the modeled point of maximum
11 impact for 70 years, 24 hours a day, 7 days a week.

12 So that's where we did more looking into activity
13 patterns and how long somebody lives at a specific
14 residence for the residential exposure duration issue and
15 how long somebody is at a job at one place. So that's
16 where we attempted to deal with that.

17 Another issue we heard a lot about is for smaller
18 footprint facilities if you look at -- and there's some
19 stuff in Appendix C. If you look at what the dispersion
20 modeling says about the points of maximum impact, it's
21 really a little tiny spot because they have a small
22 footprint. And so the assumption then would be that that
23 person is there for 70 years in that little tiny spot,
24 which of course is not realistic.

25 So we then had Air Board do a lot of work on the

1 spatial averaging for small footprint facilities to get
2 away from that conundrum of what concentration do you use
3 in your estimate of individual risk. So those are a few
4 of the things.

5 Then I think the other issue that's been
6 bothering at least the public healthers is this issue of
7 what do you do at a really big facility. Their maximum
8 exposed individual cancer risk estimate might be just
9 below what would trigger risk management, yet they have a
10 really big footprint and there is a lot of people exposed.
11 So from a population-wide perspective, using the maximum
12 exposed individual cancer risk for risk management doesn't
13 really do enough. It's not adequate. So that's where we
14 try to address this issue of, at a minimum, you have to
15 say how many people are exposed within the isopleth of de
16 minimis cancer risk and higher.

17 That was some of the feedback that we got over
18 the years. And one of the things we decided to do since
19 we had to reopen the document anyway to look at the age
20 range and exposure factors for each of those age ranges,
21 we might as well try to address, the other things we've
22 been hearing about over the years. So that's for the
23 feedback.

24 And yes, we agree that the set of recommendations
25 should be presented first and then all the stuff that

1 backs them up. And I should have listened to Stan, except
2 for he only told me that last week. So that's my excuse.

3 And the imbalance in levels of precision, we're
4 always running into that brick wall in risk assessment
5 because for some things you have a lot of data and you
6 feel you can be a little more precise. For other things,
7 like all the uncertainty factors, for example, when we do
8 a reference exposure level, we don't have a lot of data so
9 we have to use factors of ten and half logs and that sort
10 of thing.

11 So that's why you'll see that in any kind of risk
12 assessment guidance. You simply are jumping big
13 exposure -- big data gaps with assumptions. But that's
14 not to say that we didn't explain ourselves well in the
15 document where we didn't.

16 Anyway, those are my sort of instant feedback
17 comments.

18 ACTING CHAIRPERSON GLANTZ: One other thing,
19 which I think when I talked to Melanie over the last week
20 or two -- just to put it on the record. One other thing I
21 think you should do when you have these sort of summaries
22 at the beginning is for the stochastic part is to say what
23 distribution should be used and what the parameters for
24 the distribution should be. Because there's a lot of
25 places where you still are just giving percentile means

1 and percentile points. And I mean, I think that's kind of
2 left over from the way this stuff was presented before.
3 So I would also add that.

4 So anyway, anything else about sort of general
5 comments that anybody has?

6 PANEL MEMBER NAZAROFF: Can I add one since you
7 invited?

8 The list I had ordered here of the way I wanted
9 to present comments, and I cut myself off one short of
10 where I should have. So this one also fits under the
11 heading of general issue of concern in this arena of
12 potential blind spots. And I'm particularly intrigued I
13 guess because it ties into my professional interest, my
14 academic interests, with the challenges that are posed by
15 SB 352, to need to take account of conditions where
16 schools are close to roadways as part of an area of
17 concern.

18 So I was thinking about, okay, if I'm concerned
19 about children who are in a school that's 30 meters, 50
20 meters, 75 meters away from a major freeway and I have
21 diesel particulate matter and PAHs associated with that
22 diesel particulate matter, how are those kids getting
23 exposed in that school? And does the document address all
24 of the important ways in which they would be exposed?
25 And I'm not sure it does.

1 Among the concerns is this particular one. If
2 you have a PAH laden particles, 24/7 the school classrooms
3 are exposed to the emissions from the roadway. Through
4 air exchange, some of those particles will make it into
5 the school, into the classroom. They will settle on
6 surfaces.

7 I used to live pretty close to a freeway, and we
8 would get black soot accumulating on our windowsills, for
9 example. And then the kids come into the classroom and
10 they're running around and doing whatever and putting
11 their hands on their desk and putting their hands in their
12 mouth and re-suspending the particles that have been
13 settled and not cleaned. I don't know how important that
14 exposure pathway is, but I don't think it's addressed in
15 the guidance document right now. And I think it's
16 potentially significant.

17 One other line, so it's not just the particulate
18 matter that might be of concern there. I could also
19 envision that semi-volatile compounds emitted from the
20 roadway, PAHs, for example, in this three to four range
21 space where they're partitioning between the particles
22 phase and the gas phase depends upon temperature. Those
23 could be entrained from air exchange emitted from the
24 roadway, entrained through air leakage into the classroom.
25 Under cool conditions, like at 6:00 in the morning when

1 first rush hour hits, they might absorb onto the indoor
2 surfaces. And later in the day when the kids come into
3 the classroom, the day warms up, the temperatures rise
4 inside the classroom, the stuff may de-sorb and you get an
5 exposure at that time from something that was emitted
6 hours earlier and may not get picked up in an exposure
7 analysis.

8 So those are specific concerns, but they reflect
9 a broader challenge I would say that I would put as a
10 member of this Board to OEHHA to as part of the process of
11 updating the document to also take the time to re-think
12 whether all of the important exposure pathways have been
13 properly accounted for or thought about, given what we
14 currently know, not when we knew when the 2000 version was
15 assembled.

16 PANEL MEMBER FROINES: I think that's very
17 important.

18 This is John.

19 Because as we've known -- as we in our laboratory
20 know that vapor phase is particularly important. And
21 ultra-fines are particularly important. And ultra-fines
22 are important, especially from the freeway emissions. So
23 that the question is: Have we taken into account all the
24 sources of exposure?

25 DR. BLAISDELL: Bill, with respect to your points

1 about resuspension, there's a number of potential pathways
2 that can occur. And we've actually put a fair amount of
3 thought into consideration of additional pathways.

4 One of the criteria that we used when we consider
5 additional pathways is it going to be a significant risk
6 relative to other risks. In other words, if you're
7 getting a 10 to the -5 risk from ventilation, is
8 calculating the risk from a pathway that gives you 10 to
9 the -8th worth your time and the effort and the additional
10 complexity in terms of developing the model?

11 And the other consideration is are there really
12 ways to evaluate a particular pathway.

13 In terms of the resuspension example that you
14 give, there aren't any -- we looked into this in another
15 context. There aren't really good models for looking at
16 resuspension. And my -- kind of my instincts would be
17 it's probably not going to be tremendously significant
18 relative to, say, the inhalation pathway in these
19 situations.

20 We do consider -- you know, if we have a
21 semi-volatile chemical in a school, the risk assessor
22 would certainly do dermal and soil ingestion.

23 And there is a number of other examples like
24 that. Chemicals can partition from the air into plants,
25 for example. And if you apply a model, you can calculate

1 the concentration in the plan. And CalTox did that for a
2 while. It's early insignificant relative to other
3 pathways. So there's kind of that consideration.

4 PANEL MEMBER NAZAROFF: So thanks for the
5 response.

6 I agree with the broad point that one shouldn't
7 be investing lots of energy and pursuing things that
8 aren't significant contributors to exposure and risk.

9 The specific examples that I raised I don't think
10 can be dismissed. And the one of dermal -- for certain
11 chemicals, direct air to dermal, trans-dermal uptake being
12 more important than the inhalation pathway as a
13 contributor to total uptake I believe is true for some
14 chemicals, among those that are included in the Appendix
15 A.

16 And I'm not so sure about the example I've just
17 given of resuspension of particles that have accumulated
18 on a surface. But I don't think it's going to be an issue
19 of a 10 to the -5 versus 10 to the -8 where you get orders
20 of magnitude difference in what happens during the hours
21 when kids are at school versus what might happen that has
22 accumulated over time in the classroom when the kids
23 weren't at school but gets the activity in the classroom
24 leads to resuspension.

25 And even if there is not -- I mean, you guys have

1 gone through really extraordinary lengths to deal with
2 issues like contaminants getting into soil, getting into
3 homegrown food, getting taken in by a dietary pathway.

4 Even if there is not a great model today for
5 resuspension of particles that have deposited on surfaces,
6 I think you would be able to make as good a case that you
7 could make a reasonable estimate of exposure through that
8 pathway is through these more convoluted chains that are
9 already incorporated into the document.

10 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

11 MARTY: I just had a couple more comments about that, too.

12 Our soil ingestion pathway includes indoor dust.
13 So the total soil ingestion numbers we use are outdoor
14 dirt and indoor dirt. So we have considered that.

15 I don't think we have the capacity to model for
16 every single facility deposition indoors versus deposition
17 outdoors. So it has to be somewhat crude, because it has
18 to apply to all these different types of facilities. And
19 the resources aren't there to look at every facility from
20 every possible angle.

21 So we thought, and we still think, that we have
22 considered the pathways that are the most important. This
23 is not to say that there are other pathways that
24 contribute to the risk.

25 And then in terms of the skin versus inhalation,

1 I really am not at all convinced that would be true in an
2 environmental setting where you have much lower
3 concentration than in an occupational setting and no
4 protective gear. So for a couple examples. First of all,
5 the surface area of your lung is like a tennis court
6 versus the surface area of skin. And skin is a much
7 better barrier. The lung is designed to absorb gases and
8 chemicals. So I just think that in itself would tell me
9 that it's going to be orders of magnitude difference in
10 risk. So that's one issue.

11 Not having done that exercise, it's hard to say,
12 but it just seems to me overwhelming that that would not
13 be the case. For an occupational exposure where the
14 person has protective gear on for inhalation but their
15 skin is being exposed, yeah, then the skin becomes a much
16 more important route of exposure. But in a residential
17 scenario where free living people are running around being
18 exposed to air pollution, I just can't see that as being a
19 driver.

20 DR. BLAISDELL: Also, we're not the only agency
21 in the world that's ever considered these issues. I'm not
22 aware of any agency that considers dermal absorption to
23 environmental chemicals.

24 PANEL MEMBER NAZAROFF: I'm going to push back
25 because I just spent some months working on a review

1 article which is published in the In Press section of
2 Indoor Air. It was -- the lead author is Weschler,
3 Charlie Weschler. And the title is something like, "SCOC
4 Exposure Indoors, a Fresh Look at Dermal Pathways." And
5 we pulled together -- it's a literature review or a
6 critical review evaluating literature. And we pulled
7 together information from a variety of sources, including
8 such, for example, pharmaceuticals where dermal pathways
9 are used to deliver certain kinds of drugs because they
10 transmit the chemicals relatively efficiently.

11 To the point that you raised, Melanie, about the
12 surface area of the lungs versus the area of the skin and
13 the permeability of the lungs, I've spent some time
14 wrestling with that as well, because I know we're going --
15 what I'm telling you is going against the conventional
16 wisdom what people seem to think today. But I think it's
17 wrong. And part of the reason I think it's wrong is
18 because when you consider what happens in the respiratory
19 tract, that lung is designed to be efficient in the
20 transmission of gases that are not very soluble; oxygen,
21 the key one from the air into the respiratory tract.

22 The choke point, the critical resistance to
23 uptake via the lung is the amount of air that we inhale
24 for species that are easily partitioned into our dermas or
25 into our skin. And the volume of air that we inhale is

1 like a half a cubic meter an hour for adults, roughly.

2 Twelve cubic meters a day, something of that order.

3 So independent of how much surface area you have
4 in your lungs, you can't take up any more than 100 percent
5 of the half a cubic meter an hour that you inhale. Our
6 skin surface area is a couple of square meters. The mass
7 transfer coefficient -- I've sorry I have to talk a little
8 bit of the space that I know reasonably well.

9 But anyway, the critical factor that we need to
10 translate the potential for dermal uptake to a parallel
11 with the inhalation uptake is to get to a volume flow rate
12 we need a mass transfer coefficient that we would apply to
13 the surface area of the skin.

14 In indoor settings where the air flow is
15 relatively low, the product of our best estimate of that
16 mass transfer coefficient and our skin area translates to
17 about ten cubic meters per hour, 20 times larger than the
18 rate at which we inhale air. If we're outdoors where the
19 wind is blowing at a higher speed than the typical indoor
20 air movement, that ratio, that number is going to be even
21 higher.

22 So unless the skin is a good barrier, the
23 potential exists for transdermal permeation. There's more
24 delivery of material to the surface of our skin than there
25 is to the surface of our lungs in a volume per time basis.

1 And for some chemicals, it appears that the skin
2 is just not a very good barrier. And some of those are
3 included amongst the list of things that we regulate. So
4 there are experiments that have been done, not just in the
5 case that you alluded to, which I'm quite well aware of:

6 Respiratory protection in an occupational
7 setting.

8 High concentrations. People get high exposure.

9 But there are experiments that have been done
10 with a few chemicals where people have been put into a
11 chamber facility with and without respiratory protection.
12 And the amount of uptake of chemical tested through
13 subsequent excretion.

14 And the skin didn't prove to be a particularly
15 effective barrier in that case. You get 50 percent of the
16 total unprotected uptake even when there was respiratory
17 protection.

18 Anyway, I made the point. I would encourage at
19 the very least take a look at the work that was written up
20 in the paper that we've just published.

21 ACTING CHAIRPERSON GLANTZ: Which I'm sure you'll
22 be happy to give them a copy of.

23 PANEL MEMBER NAZAROFF: I will e-mail it right
24 now.

25 PANEL MEMBER FROINES: Can I ask a question? The

1 work that we've done in our laboratory clearly shows that
2 ultra-fine particles are taken up by macrophage and
3 epithelium cells. So the ultra-fines penetrate very
4 readily, whereas larger particles don't.

5 And so my question would be: If we are exposed
6 to diesel exhaust, which is mainly ultra-fines, why would
7 you -- why would one assume -- and I really don't think
8 one should -- assume that there is a dermal barrier? I
9 don't know what that barrier to cellular uptake is likely
10 to be.

11 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

12 MARTY: I think these are all -- there is uncertainty in
13 risk assessment. And we just simply don't have the
14 capability of accounting for everything. I'm worried
15 about ultra-fines and nano particles. I'm more worried
16 about nano particles in sunscreens and cosmetics and all
17 that stuff in terms of transdermal absorption.

18 But we have to stop somewhere and something that
19 essentially has to be practical to apply to so many
20 different facilities.

21 And I'm interested to see the paper about the
22 dermal absorption. I'm skeptical that it applies to a lot
23 of chemicals because, in fact, the skin is a pretty good
24 barrier for a lot of stuff. Not for Nicotine. There is a
25 great example. We know all these examples. But I don't

1 know that it's --

2 ACTING CHAIRPERSON GLANTZ: I think -- I don't
3 want to, like, beat a dead horse here. But I mean Bill is
4 going to send you the paper. I think you should look at
5 it. And then if you don't deal with it in a way which the
6 Committee thinks is appropriate, we'll tell you.

7 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

8 MARTY: We certainly can describe that that is an
9 uncertainty and may be a big uncertainty for some
10 chemicals. That's totally appropriate to put in here. I
11 don't know that we have another couple years --

12 ACTING CHAIRPERSON GLANTZ: I think that if his
13 sort of perspective turns out to be right, though, I mean,
14 it may mean that you need to add more than just -- if it
15 turns out to be real effect, then I think it needs to be
16 added into the part of the report dealing with dermal
17 stuff. And if it's not, then just make a good case why
18 not. But I think the point has now been fairly well
19 established for the next iteration of the report.

20 PANEL MEMBER FROINES: I think that it's worth
21 trying to address the chemical characteristics that create
22 the situation he's talking about. And addressing that
23 issue of the chemical characteristics could go a ways to
24 helping explain the situation.

25 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

1 MARTY: One more point that when we do a risk assessment,
2 we have -- for example, cancer slope factors. Let's pick
3 Benzene based on human exposure. Those people were
4 free-living. The Benzene was inhaled. It was there to be
5 absorbed across the skin. All of that is inherently taken
6 into account in the health value. But an exposure metric
7 is the concentration in air.

8 So, you know, in some respects, if you try to
9 develop a model to account for dermal absorption of a
10 volatile from air through the skin, maybe you're double
11 counting in terms of if you try to apply the slope factor,
12 then you would have to do something to fix the slope
13 factor to figure out what percentage of that risk is from
14 dermal. To me, it doesn't -- it's not going to be --
15 it's not going to add a lot.

16 ACTING CHAIRPERSON GLANTZ: Well, I think all I
17 would ask -- I think that's a good point, too.

18 I think the issue has been pretty well
19 ventilated. I think rather than continuing to discuss it
20 in the abstract, I think this is something you need to
21 just look at in the report.

22 Having had this fairly detailed discussion of
23 dermal exposure assessment, which is Chapter 6, maybe we
24 could see if anybody -- because I'm trying to get us
25 through the report. Does anybody have anything else -- I

1 had actually thought -- without the same level of
2 knowledge, I had certainly wondered about that myself,
3 although I didn't give you a hard time about it.

4 Does anybody else have anything about Chapter 6
5 on dermal stuff that we ought to talk about now? And then
6 we could go in order randomly to another chapter. But is
7 there anything else to say about dermal?

8 PANEL MEMBER GILL: I just had one point in your
9 presentation in the double exposure assessment level, the
10 annual double ADL. How did you come up with the value of
11 where the children under zero to two is lower than the
12 value for two to nine?

13 DR. BLAISDELL: I think the answer probably is
14 that dermal exposure for baby is less, because they aren't
15 allowed to get in contact with dirt as much.

16 PANEL MEMBER GILL: I have known a lot of
17 two-year-olds in the soil playing a lot more than actually
18 an eight-year-old is going --

19 DR. BLAISDELL: The early --

20 PANEL MEMBER GILL: That is an average of
21 thinking about that?

22 DR. DODGE: This is Daryn.

23 I think there is some evidence that the early
24 infants in the first year of age, they're being protected
25 more or less from outside environment and soil.

1 PANEL MEMBER GILL: My question is where did the
2 values comes from. Not the values, but how you derived
3 that. How did they become value? How did you come to
4 that conclusion? Because it is a fact written, but where
5 did the value come from?

6 DR. DODGE: You mean the reference?

7 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
8 MARTY: How did you get the answer?

9 DR. DODGE: I can't tell you right offhand. I'd
10 have to take a look here.

11 PANEL MEMBER GILL: Okay. I would just suggest
12 you re-look at the figure and see if it's correct or not
13 because I'm not so sure. But if it's correct, that's
14 fine.

15 DR. DODGE: Okay. Thank you.

16 ACTING CHAIRPERSON GLANTZ: So anything else
17 about dermal?

18 So let's do body weight next, which is Chapter
19 10. And I'll let Alan --

20 PANEL MEMBER BUCKPITT: In looking through
21 those -- and I realize these are the NHNES data. But I
22 wondered in looking at it if you look at some of the
23 charts that partition this out state by state, it's always
24 seemed to me that we here in California are a little
25 lighter than some of the folks.

1 So does that influence our thinking about some of
2 the issues that really pertain to a lot of the chapters in
3 this document?

4 DR. BLAISDELL: Well, we would like to have
5 California-specific data. And in some cases with our more
6 ethnically diverse population influences diet and that
7 sort of thing. It's particularly desirable. That's one
8 of the reasons why we used the fish consumption study from
9 California.

10 But you can't get NHNES data on individual
11 states. So all we have is the national data for NHNES.
12 There was a California study for body weight, but it was
13 self reported. And you know, people sometimes don't fess
14 up in terms of body weight. So the NHNES was basically
15 what we had --

16 PANEL MEMBER BUCKPITT: The best you had?

17 DR. BLAISDELL: Yeah. In terms of where we fit
18 in, I think we're around the mid-range maybe toward the
19 lower end. We're not -- we're not like Colorado. I think
20 Colorado is really low. We're not Alabama. So it's just
21 the data that we have versus knowledge are not optimal
22 often.

23 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

24 MARTY: Also, I think it's important to point out that for
25 a lot of the distributions, we had individual body weights

1 to use when we did whatever it was, per kilogram body
2 weight. So this body weight data from NHNES was used in
3 the soil ingestion estimates and the fish consumption
4 estimates where we did not have individual body weight in
5 the surveys.

6 DR. BLAISDELL: For the dietary thing, we had the
7 consumption weight and the body weight for each
8 individual.

9 PANEL MEMBER BUCKPITT: Yeah.

10 DR. BLAISDELL: Which is really preferable.

11 ACTING CHAIRPERSON GLANTZ: Anybody else? Is
12 that everything you want to talk about?

13 PANEL MEMBER NAZAROFF: One, but it's small,
14 honest.

15 ACTING CHAIRPERSON GLANTZ: No. That's okay.
16 No, this is good.

17 PANEL MEMBER NAZAROFF: And I'm just wondering
18 why with so much exquisite attention to detail that when
19 you finally get to your point estimate table in Table 8
20 you stick men and women together. Especially because, you
21 know, when we come to like third trimester exposure, there
22 is a gender bias, as there is with breast feeding. Why
23 not just leave it with separate treatment for men and
24 women all the way to the end?

25 DR. BLAISDELL: Well, in most cases, obviously

1 the third trimester case that you site does make a
2 difference. The differences in the body weight are not
3 huge.

4 You know, it's basically there is a real
5 trade-off in this model between trying to kind of keep it
6 simple, keep the calculations simple. We can do separate
7 calculations possibly for men and women in some cases.
8 But you know, you're going to have to look at the -- what
9 the tool is trying to do and the purposes that people are
10 applying. In this case, I don't think that additional
11 decision would offer a lot in the practical world.

12 PANEL MEMBER NAZAROFF: Just my reaction is I
13 find that to be a response that's sort of uneven in my
14 overall sense of the document that there are places where
15 there is a level of refinement down to percent scale. And
16 here, we're talking about a 20 percent difference between
17 men and women's body weight. And you know, to say that's
18 too difficult to take account of and yet we'll do
19 something that has sort of a one percent or five percent
20 effect just seems uneven in the treatment.

21 ACTING CHAIRPERSON GLANTZ: You know, I hadn't
22 picked up on that when I read the report. But I mean, I
23 think that is a good point. Because if you're -- I mean,
24 if you're just talking about point estimates, then you've
25 got the average person. But I think if you're doing

1 stochastic estimates -- and this is all in a computer
2 program, there is no reason that you can't. Will either
3 allow for the different distributions or have a bimodal
4 shape. That a single distribution that builds in the fact
5 that the distribution of all body weights isn't going to
6 be normal.

7 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

8 MARTY: So I think that a couple of points there that
9 these data were only used to get a body weight for the
10 soil ingestion parameters and for the fish consumption
11 parameter. The soil ingestion parameter is a point
12 estimate, because we don't have enough data on how much
13 dirt people eat to be reasonably -- to come up with some
14 reasonable distribution.

15 So in terms of stochastic approach, maybe there
16 is a difference for fish consumption on a gram per
17 kilogram weight if we separated men and women. But that
18 would be the only place where it would make a difference
19 to do that in this model, since the other parameters were
20 based on people's actual body weights.

21 DR. BLAISDELL: Again, I should point out that to
22 some extent, the refinement of the model is also based on
23 the importance to the program itself. We've reviewed
24 about 800 risk assessments. The fish consumption pathway
25 has been invoked in two. So, you know, a lot of times

1 you're looking at the pathway and the degree of
2 refinement. And certainly, you know, you can refine
3 models by going out and collecting site-specific data, for
4 example. But at that point, then it adds a huge amount of
5 the cost to the program and not an awful lot in terms of
6 value. So that's another consideration in terms of
7 looking at these pathways.

8 ACTING CHAIRPERSON GLANTZ: Anybody else have
9 anything to say about body weight?

10 So what I'd like to do now is go to Chapter 3,
11 breathing rates. Because that's probably one of the more
12 important variables in the model I think. So does anybody
13 have anything to say about breathing rates?

14 Okay. Bill.

15 PANEL MEMBER NAZAROFF: So actually, this is I
16 think a relatively simple one.

17 You expressed breathing rates volumetrically.
18 But in the state, we have people who live at different
19 altitudes and experience different pressures. And I
20 didn't see anywhere in the expression that these should be
21 volumes that are normalized to some standard temperature
22 and pressure. But I would guess that at Lake Tahoe, for
23 example, at 5,000 feet, the volumetric breathing rate is
24 going to be higher by 30 percent or something like that
25 because of the lower air pressure.

1 So it seems that one ought to either express the
2 breathing rates on a massive air inhaled per body mass per
3 time or if you're going to leave it at volume per body
4 mass per time, make it clear where you're doing the
5 exposure assessment you need to adjust to standard
6 temperature and pressure conditions.

7 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

8 MARTY: I think that would be better done at the level of
9 the districts doing the risk assessment. Because how many
10 facilities are in the mountains that are being reviewed.

11 DR. BLAISDELL: That's the thing.

12 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

13 MARTY: Almost none that I can remember.

14 DR. BLAISDELL: There aren't very many, but
15 occasionally there's something.

16 ACTING CHAIRPERSON GLANTZ: I think he's making a
17 slightly different point. And that is if you're at
18 altitude, you're going to be breathing in a different
19 volume of air. You're giving a certain amount of volume
20 per kilogram per minute. And that rate is going to be --
21 to get the same mass exposure, at altitude, that's at
22 altitude -- that would give you a lower exposure than at
23 sea level, right. So I think it's a small point, but I
24 think it's worth putting in there that the volumetric
25 breathing rates that you're given are all sea level.

1 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

2 MARTY: And then we can allow the districts to figure out
3 the adjustment.

4 ACTING CHAIRPERSON GLANTZ: And then say if you
5 were evaluating a facility that --

6 PANEL MEMBER NAZAROFF: At altitude, then you
7 have to make an adjustment. The breathing rates have to
8 go up in inverse proportion to the pressure.

9 ACTING CHAIRPERSON GLANTZ: Not the breathing
10 rate -- well, the breathing volume.

11 PANEL MEMBER NAZAROFF: The volumetric rate,
12 yeah.

13 PANEL MEMBER FROINES: I think the compromise
14 is -- Melanie is right, let the districts do it. But put
15 something in there that acknowledges the existence of the
16 issue.

17 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

18 MARTY: Yeah, John. I'm writing that down so we can put
19 that into the chapter.

20 DR. BLAISDELL: We'll have to take a look and see
21 about the data that are available for that, too.

22 ACTING CHAIRPERSON GLANTZ: So any more issues
23 around breathing rates from anybody?

24 PANEL MEMBER GILL: In Table 3-1, for example, on
25 page 32, you said that the values for infants zero to 11

1 months and it goes three months are not available data?
2 That's from the paper you sited to, is it?

3 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
4 MARTY: Uh-huh. These are BQ values.

5 PANEL MEMBER GILL: It's not available. But
6 actually, the greatest amount of data that is available is
7 actually at that age. Because if you look at infants that
8 are available -- in that particular paper, this is what it
9 stated. But the amount of data that is available for, for
10 example, children who are actually born prematurely and
11 all that, the model data that you just look at, any of the
12 hospital data you can see there is a lot of volume. You
13 just have to search for a short while. You get a lot of
14 data for infants. I don't know if that's highly impacted
15 the data at the end or not, but this data -- although the
16 paper is the paper you sited, which is Ackus-Arth &
17 Blaisdell. And this table is taken directly from that
18 particular paper. But there is a lot of information
19 available on volume rates for young infants, especially in
20 hospital settings.

21 So what I'm suggesting is that you should go back
22 and look at some of the data, not necessarily based on
23 that paper. But get additional data that is available
24 from hospital settings because there is a lot. And we
25 should be able to get that data and it's possible.

1 DR. BLAISDELL: We can take a look at that.

2 ACTING CHAIRPERSON GLANTZ: Anything else on
3 breathing? Okay. So --

4 PANEL MEMBER NAZAROFF: I have a couple of other
5 points. So I'm not sorry. I'm going make a couple other
6 points.

7 ACTING CHAIRPERSON GLANTZ: He's proud.

8 PANEL MEMBER NAZAROFF: I'm proud I'm going to
9 make my points.

10 This chapter was one where the precision police
11 should take a close look because the four and five
12 significant figures permeate the tables. You can solve
13 the problem maybe by shifting from liters to cubic meters
14 and then whacking off the two or three digits past the
15 decimal point.

16 But I also -- we just talked about the gender
17 issue for body mass. The gender issue comes up again in
18 breathing rates. It may not be as important there,
19 because when you normalize by body weight, maybe there is
20 not so much difference between men and women. But go back
21 and have a look and think about whether it makes sense to
22 lump the two genders together in these tables or whether
23 they ought to be considered as separate sub-populations.

24 I'm not expecting an answer. Just a comment.

25 DR. BLAISDELL: We'll take a look at it.

1 ACTING CHAIRPERSON GLANTZ: So anything else on
2 this chapter?

3 So Chapter 4 is soil ingestion. The one comment
4 I had -- and this is stuff I already talked to Melanie
5 about. I mean, some of the -- the distribution of soil
6 ingestion is clearly not normal, because they had at least
7 one or a couple of the studies fit their data to a normal
8 distribution and got negative soil ingestion numbers.

9 And when I teach statistics, I say if you have a
10 standard deviation that's bigger on the mean on something
11 that can't be negative, it means it isn't normal. So I
12 think that was just kind of ridiculous. And it was just
13 sort of presented as saying, well, the fact that they have
14 these negative soil ingestions means that the mean
15 underestimates the effect. I just think that's -- I
16 wouldn't have even put that in there. I would have just
17 said the study is just bad. The assumptions they made in
18 the analysis made the interpretation of the results almost
19 meaningless.

20 And then the other thing, which I was very
21 confused by in talking with Melanie and the others, they
22 said, well, the distributional data on soil ingestion is
23 so all over the place that they're not recommending a
24 stochastic approach to that and just using the point
25 estimates. And that was not at all clear to me from

1 reading the chapter.

2 So I mean, I believe given some of the bizarre
3 results of the chapter, that's a reasonable thing for
4 OEHHA to recommend. But then it needs to really be stated
5 clearly.

6 And I think going back to the discussion earlier
7 of having each chapter begin with kind of the bottom line
8 presented in a standard way where you say if you're doing
9 a point estimate model, use these numbers. If you're
10 doing a stochastic model, use this distribution with these
11 parameters. And that you would just simply say we don't
12 recommend using a stochastic approach because of the
13 limitations and the data.

14 So that's my one substantive comment on Chapter
15 4. I don't know -- did anybody else have anything you
16 wanted to add about Chapter 4?

17 Okay. So next -- this is going faster than I
18 thought it would.

19 What's the next chapter here? Breast milk. So
20 does anybody have any comments on breast milk?

21 PANEL MEMBER NAZAROFF: I do.

22 ACTING CHAIRPERSON GLANTZ: We should have made
23 him the lead person.

24 PANEL MEMBER NAZAROFF: I'm puzzled. And there
25 may be an explanation for it, but I didn't see it in

1 reading this.

2 In the equation 5-1, the dose is expressed in a
3 per day I guess averaged over a lifetime. So you divide
4 the intake that happens while an infant is breast feeding
5 by a 70 year lifetime. And I guess I understand how that
6 can make sense if we are thinking about cancer risk and
7 lifetime exposure leading to an increased risk. But is
8 there no case where one would be concerned with an acute
9 effect associated with breast milk ingestion?

10 DR. BLAISDELL: That hasn't been -- it's
11 generally not considered an acute hazard, particularly
12 with environmental exposures. The things you would be
13 concerned about is primarily cancer risk. There are some
14 chemicals with the oral reference exposure level you could
15 use with the breast milk pathway.

16 PANEL MEMBER FROINES: I didn't understand what
17 you said.

18 ACTING CHAIRPERSON GLANTZ: Did you hear what
19 John said?

20 John said, "I didn't understand the answer."

21 DR. BLAISDELL: Generally, with environmental
22 exposures, you wouldn't worry about acute effects. It's
23 the chronic effects like cancer and not long-term product
24 non-cancer effects. You have an oral reference exposure
25 level. If you had a drug or something that the woman was

1 taking, you know, you could end up with an acute
2 poisoning. But not with environmental concentrations.

3 PANEL MEMBER NAZAROFF: So then I would only
4 suggest I guess -- because it was really puzzling to me
5 why we would be dividing by 70 years at that point, that
6 qualifier be made more explicit that this is an approach
7 that applies for environmental exposures when we're
8 concerned about lifetime -- body burden or lifetime
9 exposure leading to cancer -- an increased cancer risk or
10 something like that.

11 DR. BLAISDELL: Okay. We can do that.

12 PANEL MEMBER FROINES: If a woman's exposed to a
13 chemical that metabolizes by oxidation to a more toxic
14 chemical, which could be acutely toxic, I think that's not
15 irrelevant.

16 DR. BLAISDELL: Do you have an example, John?

17 PANEL MEMBER FROINES: No, I don't offhand,
18 because I'm not sure. I mean, obviously organophosphate
19 is an issue. But I don't -- I hadn't thought that
20 through.

21 DR. BLAISDELL: They're not part of the Hot Spots
22 Program.

23 PANEL MEMBER GILL: But actually, I do not think
24 that is actually going to be a significant risk in terms
25 of acute toxicity, because under the monitoring program

1 which is toxics from an environmental exposure, I think
2 that acute toxicity would be relatively limited at all.
3 And if it occurs, it will be under a different
4 implementation rule rather than the air toxics
5 responsibility.

6 PANEL MEMBER FROINES: I guess I agree with that.
7 My concern was one that was raised earlier, which is about
8 VOCs and Toluene and Xylene, which I wasn't -- I didn't
9 come away with the feeling that it's been effectively
10 addressed in the answer. It's not necessarily irrelevant
11 is what I'm saying.

12 PANEL MEMBER NAZAROFF: I had one further point
13 on this chapter, and that has to do with equation 5-2.
14 Even within the space of how dermal exposure is handled in
15 your document, you don't seem to include dermal exposure
16 of the mother as a contributor to the breast milk
17 contamination.

18 DR. BLAISDELL: If it's not in there, its
19 omission was inadvertent.

20 PANEL MEMBER NAZAROFF: Okay. I've already
21 criticized my thinking or expressed my critical thinking
22 about how the dermal part is handled. But as a secondary
23 sort of maybe more minor point, but equation 5-2 to be
24 consistent here ought to include the dermal.

25 DR. BLAISDELL: Yes. We totally agree.

1 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

2 MARTY: It's stated on page 5-3 the minimum pathways that
3 the nursing mother's exposed to include inhalation, soil
4 ingestion and dermal --

5 PANEL MEMBER NAZAROFF: But it's not in the
6 equation.

7 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

8 MARTY: It didn't get into the equation somehow.

9 PANEL MEMBER NAZAROFF: And it would show up I
10 think absent also from equation 5-3.

11 DR. BLAISDELL: We'll make that correction.

12 PANEL MEMBER NAZAROFF: Okay. Those were my
13 comments.

14 ACTING CHAIRPERSON GLANTZ: Anything else on this
15 chapter? Okay.

16 PANEL MEMBER FROINES: I just was going to say I
17 don't have any documents with me. So I don't have -- I'm
18 at a loss. But I'll look back at the issue that Bill
19 raised earlier about breast milk and get back to Melanie.

20 ACTING CHAIRPERSON GLANTZ: Okay. So Chapter 7
21 is food, home produced food. Anybody have any comments on
22 that?

23 PANEL MEMBER FROINES: No.

24 ACTING CHAIRPERSON GLANTZ: No. Okay. Chapter 8
25 is water.

1 PANEL MEMBER GILL: This water consumption, I
2 assume you're talking about water that is taken from open
3 sources, not portable water.

4 DR. BLAISDELL: It's not municipal sources.
5 It's --

6 ACTING CHAIRPERSON GLANTZ: Right.

7 DR. BLAISDELL: And we actually don't consider
8 well water either because it's very hard to contaminate an
9 aquifer when they start with air deposition.

10 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
11 MARTY: Typical air deposition.

12 DR. BLAISDELL: Typical.

13 ACTING CHAIRPERSON GLANTZ: What is atypical air
14 deposition?

15 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
16 MARTY: Like some massive emergency releases of something
17 awful that can get into the water.

18 ACTING CHAIRPERSON GLANTZ: Oh, okay. So any
19 comments on water, Chapter 8? No. Okay.

20 How about fish, which is 9. Anything on that?
21 Okay.

22 And then I think John will have something on this
23 Chapter 11, the residential worker exposure duration
24 evaluation of short-term projects and individual versus
25 population risks.

1 As I said, the one thing I think I had mentioned
2 earlier is I think the report needs to be more explicit
3 about what people should be doing in this issue of
4 handling massly exposed individuals who are point source
5 versus some large number of people exposed in a population
6 exposure. So I think it needs to be much clearer about
7 when to use which approach. But that was my main comment
8 on that.

9 And John, you had something you had mentioned to
10 me earlier about an employment duration, was that it?

11 PANEL MEMBER FROINES: Well, I had something that
12 I decided to let it go.

13 ACTING CHAIRPERSON GLANTZ: Okay.

14 PANEL MEMBER FROINES: But, wait. My point is
15 I'm not saying with the 25-year duration. And I don't
16 really have a good sense of the distribution that one
17 might have to take into account. And so it's an issue
18 which is unresolved for me. And since I don't have --
19 since I'm concerned about it, but don't have specific
20 comments at this point, I'll follow up with Melanie.

21 ACTING CHAIRPERSON GLANTZ: Okay.

22 PANEL MEMBER GILL: I just want to follow up and
23 you used eight-hour exposure time. And that is based on
24 what criteria?

25 DR. BLAISDELL: Well, there's actually two

1 criteria. Some facilities only operate eight hours a day
2 say five days a week. And we have eight-hour breathing
3 rates for those situations.

4 The other situation, which could be applied could
5 be the off-site worker, because the off-site worker's
6 living in a facility emitting 24 hours a day is only there
7 during the eight-hour workday. So it would be applied in
8 those.

9 PANEL MEMBER GILL: That's why I'm asking eight
10 hour work days is not eight hours. It's actually a nine
11 hour workday.

12 DR. BLAISDELL: It can be adjusted in proportion
13 if you want to account for the additional period of time.

14 PANEL MEMBER GILL: The lunch hour is usually
15 spent at the facility, too, so that's why I'm asking.

16 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
17 MARTY: The districts can ask the facilities to use the
18 appropriate duration of exposure in those instances.
19 These are sort of a generic assumption of eight hours
20 someplace, school or work or wherever.

21 ACTING CHAIRPERSON GLANTZ: But it may be that
22 maybe you should change your generic assumption.

23 PANEL MEMBER GILL: If you have that assumption,
24 I suggest you say this is based on that assumption and
25 make a qualifying clause that if the work hour is slightly

1 different, then you have to adjust that estimate for that
2 particulate work hour.

3 ACTING CHAIRPERSON GLANTZ: But it might
4 actually -- since this is going to become the default for
5 all practical purposes, it may well be that you should
6 suggest using nine hours on the grounds that most people
7 are at their work site more than the normal eight hours of
8 working.

9 PANEL MEMBER FROINES: You have no way to look at
10 distribution, do you?

11 DR. BLAISDELL: The data aren't there for that,
12 John, as far as I know.

13 PANEL MEMBER FROINES: Because this whole issue
14 of eight hours, you know, has been around since the dawn
15 of time and especially since OSHA was formed. But it's
16 not accurate. People work much different hours than
17 eight hours or are exposed for more than eight hours.
18 It's something that needs -- OSHA needs to address it.
19 And perhaps not you, but it is an issue that -- the
20 duration is an issue that is poorly dealt with I think.

21 DR. BLAISDELL: Okay. We can add some language
22 that suggests accommodating different work schedules.

23 ACTING CHAIRPERSON GLANTZ: But you know, I
24 actually think that the people have raised a good point
25 here. And it may be that you should change it to nine in

1 the report. And then say -- I think you can add the
2 language that when actually doing the risk assessments
3 they could adjust it. But my guess is most people are at
4 work for nine hours a day, because of lunch and breaks and
5 such.

6 DR. BLAISDELL: Okay. We can do that.

7 ACTING CHAIRPERSON GLANTZ: It's evidenced by the
8 fact we had a 45-minute break in our work schedule today,
9 but we're in the same building for lunch. So I mean, I
10 think that's a substantive change that would be a good
11 idea in the report.

12 DR. BLAISDELL: Okay.

13 PANEL MEMBER FROINES: The question is -- I've
14 worked in factories before. And we work, you know, large
15 periods of time of overtime. But I would assume that
16 Melanie would say if the workers are working twelve hours
17 a day because of overtime, that that is something that the
18 districts would address, rather than OEHHA.

19 DR. BLAISDELL: The district would have that
20 call.

21 ACTING CHAIRPERSON GLANTZ: I think that's
22 reasonable, John. But I think if you're taking a default,
23 I think nine hours is a better default.

24 PANEL MEMBER FROINES: I'm just interested in the
25 default. That's fine with me. I'm also interested in the

1 distribution.

2 ACTING CHAIRPERSON GLANTZ: But I think they've
3 already agreed to put something about that. They don't
4 have the distributional data. But to note that in doing
5 the individual risk assessment if there is evidence that
6 people are working longer work days, that should be put
7 into the calculation.

8 PANEL MEMBER FROINES: That's fine.

9 ACTING CHAIRPERSON GLANTZ: Anything else on
10 Chapter 11?

11 Melanie.

12 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
13 MARTY: I just want to say that after rereading it a few
14 times, I realized it is a hodge-podge as Bill pointed out
15 and it definitely needs to be reorganized. So we are
16 going to make this a much nicer chapter for the next
17 version.

18 PANEL MEMBER FROINES: Which chapter?

19 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
20 MARTY: This is Chapter 11, John. Basically, what we did
21 was put a lot of concepts in there that didn't fit in
22 anywhere else nicely in the other chapters. So we have a
23 bunch of different things that are related, but it needs
24 to be more laid out better and written a little bit
25 clearer.

1 PANEL MEMBER FROINES: Good. Thank you.

2 ACTING CHAIRPERSON GLANTZ: So that takes us back
3 to Chapter 2.

4 One other thing I'd just like to -- before we do
5 Chapter 2, now there are -- half the document are
6 appendices, and which I did look through. I have to say I
7 didn't check every number in every one of the tables. But
8 the appendices were tied to the earlier chapters. So I
9 would, just assuming in a discussion, if anybody wanted to
10 say anything about an appendix, they would have; is that
11 okay?

12 PANEL MEMBER NAZAROFF: That's not what I was
13 assuming. I have some comments on appendices.

14 ACTING CHAIRPERSON GLANTZ: Before we go to the
15 dispersion modeling, which is kind of a different topic,
16 let's deal with any other comments about the appendices,
17 other than the dispersion modeling stuff.

18 PANEL MEMBER NAZAROFF: So I have comments on
19 three of the appendices, E, F, and L.

20 E deals with -- it's called determination of
21 chemical for multi-pathway analysis. But what it really
22 focuses on is the air particle partitioning. And you
23 know, I guess the first comment is that the Yuma model
24 from 1977 is pretty well outdated at this point. There's
25 been an enormous advance in our understanding of

1 especially the organics, semi-volatile organic
2 partitioning between the particle phase and the gas phase
3 that's taken place mainly in the last 15 years or so.

4 Yuma's model is based on the idea that the
5 critical particle parameter is the particle surface area
6 and that the species is adsorbing to that surface and
7 partitioning.

8 But what appears to dominate in ordinary
9 atmospheric environmental conditions is the organic
10 condensed phase material into which other organics
11 dissolve so it's an AB absorption phenomenon rather than
12 an absorption phenomenon.

13 And I don't think you're probably off by large
14 factors, but this chapter or the appendix should really be
15 updated to reflect the current understanding of how SVOCs
16 partition between the gas phase and the particle phase.

17 One of the key clues to me is the -- in the notes
18 to you, I said that the references are long in the tooth,
19 most of them are prior to 1995, which was for me kind of
20 when the watershed happened and people really started
21 understanding this process outdoors.

22 So anyway, I would commend to your attention kind
23 of some of the latest literature in this area and think
24 about reframing the partitioning as the SVOCs going
25 into --

1 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

2 MARTY: Organics.

3 PANEL MEMBER NAZAROFF: Organics in the condensed
4 phase, rather than sitting on surfaces.

5 On F, here we are with dermal again. Maybe I
6 don't have any more points, but let me check to be sure.

7 No, actually, I do. Because this is your
8 treatment of dermal, which again was soil gets
9 contaminated. People get the soil on them. And then they
10 get some dermal exposure.

11 So I had a couple comments I haven't made yet on
12 that. First, I think you have done this reasonably, but I
13 don't know the literature well enough to be sure. So I
14 just want to call to your attention an article published
15 by John Kissel in 2011 in Journal of Exposure Science and
16 Epidemiology. It's called, "The Mismeasure of Dermal
17 Absorption." And he takes a hard look at the sets of
18 empirical studies in which contaminated soil is applied to
19 skin. And then the fraction of the contaminant that's in
20 the soil that gets through the skin is determined. And he
21 makes the key point that if you make the soil layer
22 thicker and thicker, that percentage goes down.

23 I saw that reflected in your appendix so maybe
24 you've already captured the central ideas. But the
25 literature citations were a bit old again so I just want

1 to have you take a look at Kissel's latest paper on this
2 topic to make sure that his current understanding and your
3 thinking about this in this document are consistent.

4 DR. BLAISDELL: We can do that.

5 PANEL MEMBER NAZAROFF: I had one other specific
6 point, which had to do with -- shows up on page F-15. And
7 it addressed kind of default parameter values. And I'm
8 not sure -- I read this part kind of quickly, so I'm not
9 sure I captured the key idea. So I'm going to parrot to
10 you what I think the key idea was and what I'm concerned
11 about about it and then you can correct my
12 misunderstanding if it existed.

13 Basically what I got was that for organic
14 compounds, kind of a default absorption coefficient would
15 be ten percent. And for metals, a default absorption
16 coefficient would be one percent. And you presented an
17 argument that these numbers were kind of well within the
18 range of what -- when you had specific data, what those
19 specific data would show for those classes of compounds.

20 My concern comes up with the metals because the
21 numbers that you present are in the range of .2 to 4
22 percent. If in the absence of data one were to pick one
23 percent and say this is an appropriate default assumption,
24 do you run the risk of being a factor of four away from a
25 conservative position, which is what I think you ought to

1 be for the first screening level analysis in the absence
2 of specific data pick a conservative number, not a number
3 in the middle of the range. So my sense was from what was
4 presented here that that default number ought to be four
5 percent, not one percent.

6 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

7 MARTY: We'll go through the document and take another
8 look at it. I think that's a hangover from the last
9 version and we didn't actually think too hard about that.

10 DR. DODGE: Yeah, I think I only applied the one
11 percent in a few cases where I didn't have very good data
12 or very much. That was for selenium and for fluoride.
13 And the data I had suggested those two chemicals really
14 don't get across the skin very easily. And it's probably
15 not four percent. At best, it's probably one percent,
16 somewhere around this sort of default factor that was
17 published some years ago when people first started looking
18 at dermal absorption.

19 PANEL MEMBER NAZAROFF: That may be right. And I
20 guess my point is just to go back and have another look at
21 the way that that particular issue is handled to make sure
22 that if you apply it in a screening sense in the absence
23 of specific data, for example, for metal salts where you
24 don't have an empirical basis to know what the absorption
25 coefficient is.

1 DR. DODGE: Right. That's a good point. I think
2 four percent would be too high for these particular
3 chemicals. But yeah.

4 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
5 MARTY: We will re-evaluate and look at where we can apply
6 it and see if that should have been a different number.

7 PANEL MEMBER NAZAROFF: And then my last comment
8 that I want to raise is from Appendix L. And I haven't
9 got my brain completely wrapped around this, but it seems
10 to me the retrospective question -- how long have you
11 lived in your current residence -- doesn't give an
12 unbiased estimate of what you want for health risk.

13 I'm just thinking about my own case. I've lived
14 in my house for 25 years. I'm in my 50s. I'll probably
15 live there another 20 years before I reach the end game.
16 And the right answer for me, if there was an exposure
17 facility or some kind of industrial release facility ought
18 to be 45 or 50 years, not 30 years, even though 30 years
19 is pretty close to the answer I would give you for how
20 long I've lived in this space.

21 So you're using empirical data on people's
22 response to how long have you lived in your current
23 residence as a basis to decide what's an appropriate
24 duration of an exposure appraisal. And I'm just concerned
25 that you're biased in the wrong direction. If I had to

1 stick my finger up in the air and give you a number to
2 work with, I'd say if you're going from birth until
3 adulthood, use 20 or 21 years or whatever. And then if
4 you're talking about adults, you know, let's take --
5 again, if it's a screening or a point level estimate,
6 let's take 50 years, the time between when you're first an
7 adult and the sort of end of a normal life span.

8 PANEL MEMBER GILL: If I take a look at my
9 neighborhood, for example, I think 30 years probably may
10 be too high.

11 PANEL MEMBER BUCKPITT: My too.

12 PANEL MEMBER NAZAROFF: Well, if you live in a
13 neighborhood that was recently built, it's definitely too
14 high. That's another bias. If you ask the question in
15 California now and do it across the state's population,
16 because of the influx of people, there's many houses that
17 didn't exist 50 years ago that exist today. So you can't
18 get an answer that would be 50 years. And yet, in
19 established neighborhoods where there are old houses, you
20 can find people who have lived there quite a long time.
21 And again, I didn't get my brain completely wrapped around
22 this, but I wasn't really satisfied with the approach.

23 DR. BLAISDELL: You're absolutely right. The
24 data that are used to estimate residential duration are
25 not what we want. But they are what we have, both

1 nationally and the data in California. And what you
2 really would like is longitudinal data on individuals.
3 But we just don't have it. You can't get it from the
4 census.

5 ACTING CHAIRPERSON GLANTZ: But I think he's
6 making a little different point. That's if you ask people
7 how long they lived at a given location, that's how long
8 have they lived there as of today. That doesn't count the
9 additional time that they're likely to live there. So you
10 have sort of censored data.

11 DR. BLAISDELL: Absolutely.

12 ACTING CHAIRPERSON GLANTZ: So it may be that you
13 ought to make some kind of adjustment to try to take into
14 account the censory -- maybe you could cross link that
15 with age distribution data or something.

16 But that's a good point. I mean, it is going to
17 underestimate the time.

18 DR. BLAISDELL: There is no question that the
19 data are --

20 ACTING CHAIRPERSON GLANTZ: So you ought to try
21 to guesstimate some --

22 DR. BLAISDELL: We would absolutely -- based on
23 what we've looked at, I think we would be pulling a number
24 out of a hat.

25 One of the reasons why we kind of stuck with the

1 9, 30, and 70 is that those are consistent with what U.S.
2 EPA has used. And you know, it's based on this absolutely
3 imperfect survey questioning. I mean, somebody could have
4 lived 50 years and moved last week to an old folks home,
5 and the answer would be I've lived here two months. And
6 actually the same thing applies to the worker data on the
7 job.

8 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

9 MARTY: At the same time, you may have the same
10 probability of asking somebody who's been in their house
11 for 60 years and the answer is 60.

12 So we're aware that it is a problem, and I agree
13 with you it's like really hard to get your head around,
14 much less how to correct for that. But maybe a little
15 more discussion is in order of that.

16 PANEL MEMBER NAZAROFF: It also seems like using
17 an estimator that you know is biased because the data are
18 available, that's not, to me, clearly superior than making
19 a reasonable judgment based on kind of common sense often
20 people rely on that in an exposure world as well. And you
21 can justify the common sense argument maybe better than
22 you can to correct for a biased estimator based on a
23 question that is not giving you the answer that or the
24 data that you need to do this in an unbiased fashion.

25 PANEL MEMBER FROINES: I also think one of the

1 goals of this is to improve our exposure assessment to
2 affect public health protection and prevention. And I
3 think that if we are going to have pro public health as a
4 goal, then we have to think about what are the larger
5 exposure estimates might suggest.

6 ACTING CHAIRPERSON GLANTZ: Well, I agree with
7 that.

8 So let's go back to Chapter 2. I had just one
9 kind of picky question, just to show people I read it. If
10 you look on page 227 in the second line, you're talking
11 about adjusting if a factor only operates five days a week
12 out of seven. And you're saying apply a factor of seven
13 over five. It seems to me it ought to be five over seven.
14 Am I missing something? It's on page 227, the second
15 line. Seemed like what we had there was backwards, but it
16 may be I'm not understanding. What you're doing is
17 adjusting if a factory doesn't operate every day.

18 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
19 MARTY: It's to multiply of the annual average. It's
20 because the model has annualized.

21 DR. BLAISDELL: You're right. I'm sorry.

22 ACTING CHAIRPERSON GLANTZ: Those two numbers are
23 upside down.

24 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF
25 MARTY: We will check with that.

1 ACTING CHAIRPERSON GLANTZ: I just wanted to
2 demonstrate for the record I did read this thing.

3 So anyway, anybody have any other comments
4 about -- I have a bunch of little things in this chapter,
5 but I'll just give them to you.

6 So did anybody else have any comments on Chapter
7 2. Either of you guys? You're the most chatty guy today.

8 PANEL MEMBER NAZAROFF: I'm sorry. I'm not
9 sorry. I'm really proud that I'm the most chatty one.

10 ACTING CHAIRPERSON GLANTZ: You should be proud.
11 We're going to give you an award.

12 PANEL MEMBER NAZAROFF: The gold star.

13 ACTING CHAIRPERSON GLANTZ: The gold star.

14 PANEL MEMBER NAZAROFF: There are two issues that
15 I want to bring up on the meteorologic part of the system,
16 the dispersion part. One has to do with calms and how
17 those are handled. So I know -- and it's stated here that
18 AERMOD, the recommended dispersion model now, doesn't
19 incorporate calm conditions. And just for everybody's
20 sort of background, the wind speeds measured at some
21 meteorologic monitoring station, there is distribution by
22 hour of the recorded values. But then there are some
23 hours where the wind speed is below the minimum reporting
24 level, half a meter per second or a meter per second,
25 whatever the particular condition is. And in that case,

1 the answer is reported as calm.

2 And when you try to put that into a standard
3 Gaussian plume dispersion model, you get an indeterminate
4 answer because you divide by wind speed. So it's a
5 fundamental problem in Gaussian modeling. The statement
6 in here on page 228 is that U.S. EPA's policy is to
7 disregard calms until such time as an appropriate
8 analytical approach is available. That's probably okay
9 for risk management and risk protection for elevated
10 sources, because calm conditions are not going to produce
11 extraordinarily high exposures when the source is emitting
12 aloft.

13 But when you have ground level emission sources,
14 those are the worst times. The calms actually have the
15 highest associated local exposure impacts. And so again
16 the kids who were in a school that's close to a roadway
17 and the conditions -- if the conditions that are calm are
18 not accounted for, then there will be a systematic bias in
19 the exposure assessment. It's going to be tens of percent
20 of impact.

21 Calm conditions, I've looked at these data for
22 some other purposes occur about ten percent of the time.
23 And the conditions that are just above calm contribute on
24 average something like 30 percent of one's exposure for a
25 ground level release event. So the calm conditions could

1 make a significant contribution.

2 There is a comment -- I mean, this statement on
3 228 concerns U.S. EPA's policy. What I couldn't tell for
4 sure was what happens in this modeling protocol, 238 says
5 that under regulatory options includes calms and missing
6 data processing routines. But I don't know what that
7 means, and the text didn't elaborate.

8 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

9 MARTY: We will talk with ARB about that.

10 But my understanding, which is, albeit limited,
11 on this dispersion model are that the calms aren't
12 completely ignored. They're set to the lowest threshold
13 that would be defective. So half a meter per second or
14 whatever it is. So it's kind of like, okay. We have all
15 these calm hours. We'll just treat them as if they were
16 at the threshold. But I could be wrong about that.

17 PANEL MEMBER NAZAROFF: Coincidentally, unrelated
18 to my position on this Committee, we've been talking with
19 U.S. EPA about their NATA assessment, National Air Toxic
20 Assessment, particularly with respect to vehicle
21 emissions, an area I'm currently interested in. And we
22 had an e-mail exchange with them recently on exactly this
23 point asking them how they handled the calm conditions for
24 assessing population exposure to vehicle emissions in the
25 NATA assessment. And the answer we got back was they were

1 ignored. They were censored out of the data that were
2 analyzed. So what you got was the average for everything
3 that was not calm. And a biased outcome as a result.

4 The one other point had to do with deposition,
5 which shows up, of course, I guess mainly in the
6 multi-pathway exposure assessment. And if I understand
7 properly, any contribution of deposition to reducing
8 airborne and inhalation exposure is neglected but then --
9 and I think that's fine. And then the deposition is
10 necessary in order to account for soil contamination and
11 other things of this sort.

12 So page 241, it says, "Deposition algorithms are
13 unavailable in the initial release of AERMOD. U.S. EPA is
14 developing deposition algorithms. Check with U.S. EPA for
15 availability."

16 Is that current information?

17 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

18 MARTY: I don't think so. That's another question for
19 ARB.

20 DR. BLAISDELL: We'll talk to ARB about that.
21 But however they deal with deposition, it wouldn't be
22 ignored because it's really integral for our risk
23 assessment model. They might use ISC. ISC is to estimate
24 deposition or something like that. I don't know. But
25 you're definitely right; it needs to be clarified.

1 PANEL MEMBER NAZAROFF: Those are my comments.

2 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

3 MARTY: I still think it's the case that they don't look
4 at the depletion of the plume. So there is a little bit
5 of double counting.

6 PANEL MEMBER NAZAROFF: Right, which probably is
7 a small enough issue if one is aiming to be health
8 protective to not be concerned about, because deposition
9 in the near field isn't going to be a major loss mechanism
10 for the air concentrations for the things we're concerned
11 about.

12 AIR TOXICOLOGY AND EPIDEMIOLOGY BRANCH CHIEF

13 MARTY: Unless they're sending rocks out to stack.

14 PANEL MEMBER NAZAROFF: That's right. No gravel
15 intake exposure would be accurate without accounting for
16 deposition.

17 ACTING CHAIRPERSON GLANTZ: Any chapters on
18 Chapter 2? Any other comments on anything? I think we've
19 worked our way through the report.

20 Well, so here's what I would suggest. I mean, I
21 think the discussion -- notwithstanding, I think the
22 document's actually in pretty good shape. I think there
23 have been a few substantive issues raised that I think you
24 need to deal with. But most of the criticism has been
25 about the presentation I think. And I would hope that we

1 would be able to act on this report at the next meeting.

2 Now, there are a couple of very experienced
3 people who often have opinions who aren't here today. And
4 so what I would ask the OEHHA to do is to reach out to
5 Paul Blanc and Kathy Hammond. And I'm blanking on who
6 else isn't here.

7 PANEL MEMBER FROINES: Jesús, Beate Ritz.

8 ACTING CHAIRPERSON GLANTZ: Yeah. And just try
9 to work with them on the phone and get any additional
10 comments that they have so that hopefully when the report
11 comes back next time, we can approve it. Obviously, it's
12 going to be a next draft circulated to people. But I'd
13 hate to have to have this drag on for another meeting if
14 we can avoid it.

15 So the next item on the agenda is consideration
16 of request to have oral testimony at the meetings. And
17 again, we have kind of a light turnout this time,
18 unusually light actually. So I don't want to make any
19 decisions on this. This is an issue since I've been on
20 this Committee like almost as long as John has, this is an
21 issue that comes up from time to time. The Committee in
22 the past has been of the view that we didn't want to take
23 oral testimony because the issues before us are quite
24 technical and the feeling was that having the material
25 submitted in advance of writing gave people a chance to

1 look at it and think about it. That certainly has been my
2 personal view. But I think if anybody wants to express --

3 PANEL MEMBER FROINES: Let's leave it for next
4 time.

5 ACTING CHAIRPERSON GLANTZ: Okay. I think we
6 should leave it for next time. In deference to our real
7 chair. But so is that okay, Jim?

8 MR. BEHRMANN: Yes.

9 ACTING CHAIRPERSON GLANTZ: But do think about it
10 and we'll talk about it next time.

11 That's all the business I know of. Does anybody
12 else have any consideration of administrative matters?

13 So do we need a motion to adjourn or can we
14 just -- somebody move --

15 PANEL MEMBER GILL: So moved.

16 PANEL MEMBER FROINES: You need a motion.

17 ACTING CHAIRPERSON GLANTZ: You move.

18 PANEL MEMBER GILL: I move you adjourn the
19 meeting.

20 PANEL MEMBER BUCKPITT: Second.

21 ACTING CHAIRPERSON GLANTZ: Any opposition?

22 Okay. Well, thank you all. This was a big report and I
23 think you guys made a lot of good comments.

24 (Whereupon the ARB Scientific Review Panel
25 adjourning at 2:44 p.m.)

